Document:

EX-10.18

 Exhibit 10.18 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 DEVELOPMENT AND CLINICAL MANUFACTURE
AGREEMENT 
 This Development and Clinical Manufacture Agreement (the “Agreement”) is made and entered into as of 30 April
2012 (the “Effective Date”) by and between METABOLEX, Inc., a Delaware corporation with its principal place of business located at 3876 Bay Center Place, Hayward, California 94545 (“METABOLEX”) and
SIEGFRIED AG, a Swiss Company, with its principal address place of business located at Untere Brühlstrasse 4, Zofingen CH4800 Switzerland (“SIEGFRIED”). METABOLEX and SIEGFRIED may be referred to herein individually as a
“Party” or collectively as the “Parties”.  
 RECITALS 

METABOLEX desires SIEGFRIED to perform certain manufacturing process development work on its proprietary drug compound known as “MBX-102” (also
known as “arhalofenate”) in accordance with the terms and conditions set forth in this Agreement. This Agreement also allows SIEGFRIED to manufacture and supply to METABOLEX quantities of this drug compound in accordance with the terms and
conditions set forth in this Agreement. 
 SIEGFRIED is willing to perform such development work and potentially to manufacture MBX-102 for METABOLEX under
the terms and conditions set forth in this Agreement. 
 Now therefore, the Parties agree as follows: 

 

	1.	DEFINITIONS 

  

	 	1.1.	“Affiliate” means, with respect to a particular Party, any person, other corporation or other legal entity that controls, is controlled by or is under common control with such Party. For purposes of
this definition, the term “control” (with correlative meanings for the terms “controlled by” and “under common control with”) means that the applicable entity has the actual ability to control and direct the management
and business of the particular Party, whether through ownership of voting capital shares or similar voting securities of such Party, or by contract or otherwise. 

  

	 	1.2.	“Applicable Law” means all applicable laws, rules, ordinances, and regulations, including any rules, regulations, guidelines or other requirements of relevant government agencies, that may be in
effect from time to time in the applicable country or jurisdiction, including then-current Good Manufacturing Practices applicable to the Services to be provided under this Agreement. 

 

	 	1.3.	“Compound” means the chemical compound known as MBX-102, having the chemical structure as described in Exhibit A of this Agreement. 

 

	 	1.4.	 “Confidential Information” means, with respect to a Party, all Information, including but not limited to data, deliverables,
know-how, chemical structure of the Compound, information contained in a Plan, information contained in or related to Intellectual Property, and technical 

	 	
and non-technical materials, that such Party delivers to the other Party pursuant to, or in connection with, this Agreement, regardless of its source, and whether or not the same is specifically
identified as being “confidential”. This Agreement constitutes Confidential Information of both Parties. In addition, but subject to the limitations set forth in Section 7.3, all Information that: (i) is disclosed by METABOLEX to
SIEGFRIED regarding the Services to be provided under this Agreement; (ii) is set forth in a Plan; (iii) is developed or generated by SIEGFRIED as a result of performing Services under this Agreement, including the Data and Deliverables;
or (iv) comprises the Compound or otherwise is directly related to the Compound, shall be deemed to be Confidential Information of METABOLEX. Confidential Information also includes information disclosed by the Parties under the Non-Disclosure
Agreement of February 28, 2012 (among METABOLEX, SIEGFRIED and Cilag AG) and under the Non-Disclosure Agreement of January 31, 2012 (between METABOLEX and SIEGFRIED). 

 

	 	1.5.	“Controlled” means, with respect to a specific material, item of Information or Intellectual Property right, that the applicable Party owns or has a license to such material, item or right and has the
ability to grant the other Party access and a license thereto as provided for in this Agreement without violating or conflicting with any agreement with or rights of a Third Party. 

 

	 	1.6.	“Current Good Manufacturing Practice” or “cGMP” means the then-current standards for the manufacture of fine chemicals, active pharmaceutical ingredients, intermediates, bulk products
or finished pharmaceutical products set forth (i) in 21 U.S.C. 351(a)(2)(B), in U.S. FDA regulations at 21 C.F.R. Parts 210 and 211 and in The Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice
for Medicinal Products, each as may be amended from time to time; (ii) in International Conference on Harmonization (ICH) Guidelines relating to the manufacture of active pharmaceutical ingredients and finished pharmaceuticals as may be amended
from time to time; (iii) all other similar Applicable Laws relating to the manufacturing of active pharmaceutical ingredients and promulgated by any other governmental authority having jurisdiction over the manufacture of drug compounds in the
countries in which the Product containing Compound will be used or sold; and (iv) all additional regulatory authority documents or regulations that replace, amend, modify, supplant or complement any of the foregoing. 

 

	 	1.7.	“Deliverable” or “Deliverables” means, respectively, each individual item or collectively all items that SIEGFRIED agrees to provide to METABOLEX pursuant to Section 6.1.

  

	 	1.8.	“FDA” means the United States Food and Drug Administration, or any successor thereto having the administrative authority to regulate the development and marketing of human pharmaceutical products in the
United States. 

  

	 	1.9.	“Information” means any and all information of any kind, including results, data, discoveries, improvements, processes, methods, protocols, formulas, techniques, inventions, know-how and trade secrets,
scientific, chemical, pharmaceutical, toxicological, biochemical, and biological, data, and information relating to the results of tests, assays, methods, processes, and specifications, and/or other documents containing information and related data,
and any assay control, regulatory, and any other test results or information, regulatory, manufacturing, financial and commercial information or data. 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 2 

	 	1.10.	“Intellectual Property” or “IP” means patents, trademarks, copyrights, trade secret rights, rights in proprietary, confidential Information, and any other similar rights in any intellectual
property as conferred or established by the laws of any jurisdiction, and all applications for any such rights. 

  

	 	1.11.	“Plan” means the Process Development Plan, the Manufacturing Plan and any agreed upon Scope of Work. 

  

	 	1.12.	“Project” shall mean a specific set of Services to be performed by SIEGFRIED for METABOLEX as set forth in a Plan. 

  

	 	1.13.	“Quality Agreement” means the Quality Agreement to be entered into by the Parties as described in Section 2.6. 

 

	 	1.14.	“Raw Material” means the specific starting materials (including purchased intermediates) that are used in the manufacture of the Compound, as provided in this Agreement, including materials that are
consumed during such manufacturing process. “Raw Materials” are listed in Exhibit A of this Agreement. 

  

	 	1.15.	“Services” means the process development, manufacturing and other services performed by SIEGFRIED under a Plan and in accordance with the terms of this Agreement. 

 

	 	1.16.	“Specifications” means the characteristics, processing requirements, standards and other specifications related to the Compound as agreed to by the Parties and set forth in the applicable Plan
(Exhibit B, Exhibit C and/or Exhibit D) of this Agreement, as may be amended or supplemented from time to time by mutual agreement of the Parties. 

 

	 	1.17.	“Third Party” means any entity or individual other than METABOLEX and SIEGFRIED and the Affiliates of either Party. 

 

	2.	PURPOSE; SCOPE; PROCESS DEVELOPMENT AND MANUFACTURE  

  

	 	2.1.	Purpose and Intent. The Parties agree that SIEGFRIED shall, pursuant to the terms of this Agreement, perform: (i) process development Services to improve and scale-up the manufacturing process for bulk
Compound manufacturing, (ii) potentially manufacturing Services to supply to METABOLEX amounts of bulk Compound in accordance with the Specifications, for use in clinical materials, and (iii) potentially other Services relating to Compound
manufacture, as set forth in one or more Scope of Work documents as agreed to by the Parties. SIEGFRIED will use good faith, commercially reasonable diligent efforts to provide all of the agreed Services as requested by METABOLEX and set forth in a
Plan. 

  

	 	2.2.	Process Development. SIEGFRIED shall perform the process development Services and tasks and activities as set forth in the agreed upon process development plan attached hereto as Exhibit B (the
“Process Development Plan”), as such plan may be amended from time to time by the written agreement of the Parties. Such Services shall include the preparation and delivery to METABOLEX of the Deliverables as set forth in the Process
Development Plan. 

  
 [*] = Certain confidential information contained
in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 3 

	 	2.3.	Manufacture. If the Parties agree on a manufacturing plan (“Manufacturing Plan,” Exhibit C) and execute a Quality Agreement (see Section 2.6), SIEGFRIED shall manufacture and
supply to METABOLEX the bulk Compound in such quantities as ordered by METABOLEX in orders submitted to SIEGFRIED from time to time by METABOLEX in accordance with the Manufacturing Plan, which may be amended from time to time by the written
agreement of the Parties. The Manufacturing Plan shall cover all relevant terms for such manufacture and supply, including sales price, applicable Incoterms, any additional Deliverables, whether specific Raw Materials will be supplied by METABOLEX
or by SIEGFRIED from a qualified vendor, the manufacturing process to be used, whether the manufacturing is to be performed under cGMP, [*], an agreed [*], an agreed [*] and any other relevant information associated with the execution of the
manufacturing work. All such bulk Compound manufactured and supplied under the Manufacturing Plan shall be manufactured in compliance with cGMP (except as otherwise specified in the Manufacturing Plan) and all other Applicable Laws and shall comply
with the Specifications. The ordering and delivery of such Compound under the Manufacturing Plan shall be in accordance with the provisions of the Manufacturing Plan. 

 

	 	2.4.	Additional Projects. If METABOLEX desires that SIEGFRIED perform certain additional activities or tasks relating to process development or manufacturing of Compound that are outside the scope of the Process
Development Plan or the Manufacturing Plan, METABOLEX shall submit a written request to SIEGFRIED setting forth in reasonable detail the particular activities or tasks requested for such proposed additional Project. The Parties shall then negotiate
reasonably and in good faith and seek to agree on a written “Scope of Work” setting forth such additional activities and tasks, and the specific terms for such proposed Project (which activities and tasks shall, upon agreement by
the Parties to such Scope of Work, be deemed additional Services to be performed hereunder). Each such Scope of Work shall include a specific description of the particular Services to be performed and the budget, costs and timeline therefore, and
all Deliverables to be prepared and delivered to, and, as necessary, any additional Information and requirements for such Services. Upon the Parties agreeing on such a Scope of Work, it shall be attached to this Agreement as Exhibit D
and shall be deemed incorporated herein, and the Services covered by such Scope of Work shall be deemed to be a new Project hereunder. Each agreed Scope of Work may be modified or amended from time to time upon mutual written agreement of the
Parties, and such agreed-upon modifications or amendments shall be attached as part of Exhibit D and deemed incorporated into the applicable Project. It is contemplated that there may be multiple Scopes of Work that shall be
sequentially numbered, each referencing and covering a different Project. An exemplary “Form of Scope of Work” is attached hereto as Exhibit D. 

 

	 	2.5.	Conflicting Terms. The Parties agree that if there is any conflict between a particular term of a Plan and the terms of this Agreement, the terms of this Agreement shall control and supersede such conflicting
term of the applicable Plan, unless such Plan specifically and expressly provides that such term shall prevail notwithstanding such conflict. 

  

	 	2.6.	Quality Agreement. Prior to SIEGFRIED commencing work for METABOLEX under a Manufacturing Plan, SIEGFRIED and METABOLEX shall enter into a quality agreement governing the quality systems used in connection with
SIEGFRIED’s performance (the “Quality Agreement”). 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 4 

	 	2.7.	Schedule and Performance. SIEGFRIED will schedule the performance of each of the Projects (including all Services under the Project and delivery of all Deliverables) as specified in the Plan applicable to the
Project and will coordinate with METABOLEX as appropriate to ensure the timely commencement and performance of all such Services. SIEGFRIED shall perform all the Services and other work under a Project in accordance with the terms of the applicable
Plan, Applicable Law, and the terms and conditions of this Agreement. SIEGFRIED shall perform all the Services and other work under this Agreement using good faith, reasonable care and in accordance with industry practice. SIEGFRIED shall [*]
provide the facilities, all supplies and Raw Materials (other than any specific materials to be provided by or on behalf of METABOLEX under the terms of a particular Plan) and staff necessary to complete all the Services and work in accordance with
the terms of this Agreement and the applicable Plan. All such staff shall have all training, education and experience needed to perform the applicable Services in a competent and efficient manner. Notwithstanding anything in this Article, the
Parties acknowledge and agree that the Projects and the Plans may need to be adjusted and adapted depending on the progress and interim results of the activities performed by SIEGFRIED under this Agreement. The Parties further acknowledge that
SIEGFRIED shall be compensated based on the works done under this Agreement, rather than based on achievement of specific results. 

  

	 	2.8.	Raw Materials. In the preparation of Compounds, SIEGFRIED agrees to use only those Raw Materials that are supplied by METABOLEX or obtained by SIEGFRIED from a qualified vendor. SIEGFRIED shall determine the
amounts of Raw Materials that SIEGFRIED will need to make the Compound ordered by METABOLEX. Any Raw Materials supplied by METABOLEX to SIEGFRIED shall only be used for Services associated with METABOLEX Projects, unless otherwise agreed.

  

	 	2.9.	Excess Material. At the conclusion of a Plan or upon expiry or termination of this Agreement, SIEGFRIED shall provide notice to METABOLEX of any excess Raw Material and/or Compound (the “Excess
Material”) requiring disposal. METABOLEX shall instruct SIEGFRIED within [*] calendar days of receipt of such notice, whether SIEGFRIED shall deliver such Excess Material to METABOLEX (or to a METABOLEX designated Affiliate or Third Party)
or otherwise dispose of such Excess Material. In the event that METABOLEX does not instruct SIEGFRIED within the above mentioned [*]-day period, SIEGFRIED may dispose of the Excess Material in its sole and absolute discretion without any further
liability or obligation to METABOLEX. In any event, METABOLEX shall [*] (i) the delivery of Excess Material to METABOLEX (or to a METABOLEX designated Affiliate or Third Party) and/or any other disposal of Excess Material by SIEGFRIED.
METABOLEX shall [*] (i) [*] excess Raw Material, and (ii) [*] excess Compound. 

  

	 	2.10.	Subcontractors. SIEGFRIED may not subcontract any of the Services or other work to be performed by it hereunder without METABOLEX’s prior written consent. In the event that METABOLEX does so consent, then
any agreement entered into by SIEGFRIED with the permitted subcontractor shall, at a minimum, provide for ownership and allocation of Intellectual Property rights and for obligations of confidentiality of Information, record-keeping, access, rights
to data, and performance in accordance with Applicable Law that are consistent with the intent and terms of this Agreement and the Quality Agreement. SIEGFRIED shall remain liable for the performance of any of its obligations hereunder that it
delegates to a subcontractor. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 5 

	3.	PAYMENTS  

  

	 	3.1.	Compound Purchase Prices and Services Prices. The Manufacturing Plan shall provide the fixed price for the Compound manufactured and supplied to Metabolex by SIEGFRIED under such Plan. The Process Development
Plan shall provide for the specific prices charged for the Services performed under such Plan, with such prices tied to the specific Services to be performed, it being understood and agreed, however, that SIEGFRIED shall be compensated based on the
Services actually performed under such Process Development Plan in accordance this Agreement, rather than based on achievement of specific results or milestones. In the event that SIEGFRIED expects that it will be unable to perform the Services
under a Process Development Plan or to significantly delay or deviate from the Process Development Plan, then SIEGFRIED shall so inform METABOLEX without undue delay. The Parties then shall discuss such matter and seek to mutually agree on an
amended Process Development Plan. 

  

	 	3.2.	Expenses. METABOLEX shall reimburse SIEGFRIED for any out-of-pocket costs and expenses of SIEGFRIED incurred in connection with conduct of the agreed Services under a Plan, to the extent that such costs and
expenses are set forth in the Plan or otherwise have been mutually agreed to in writing by the Parties (such amounts, the “Expenses”). 

  

	 	3.3.	Payment Terms. SIEGFRIED will invoice METABOLEX for the payment amounts owed for the Services actually performed under the Plans and for the Expenses on a monthly basis. SIEGFRIED will further invoice METABOLEX
for the purchase price for Compound upon delivery of such Compound. Any such invoice shall provide specific details as to the payment obligation and the basis for such obligation. All payments of undisputed amounts on such invoices shall be due
within [*] calendar days following the invoice date. The invoice shall reference this Agreement and the relevant Plan, be accompanied by sufficient back-up documentation, if any, necessary for SIEGFRIED to support the payments being invoiced, and
shall be sent to: 

 METABOLEX, Inc. 

3876 Bay Center Place 
 Hayward,
CA 94545 
 Attention: Accounts Payable 

Fax: (510) 293-6853 

Unless otherwise agreed in writing by the Parties, (i) all amounts payable hereunder and under the Plans shall be invoiced and paid in
U.S. Dollars and (ii) any required conversion of amounts in Swiss Francs, Euros or other currencies into U.S. Dollars shall be made in accordance with SIEGFRIED’s standard accounting policies. 

 

	 	3.4.	Acceptance of Compound and Services. METABOLEX shall have the right to review and test all Compound delivered by SIEGFRIED under the Manufacturing Plan to confirm that such delivered Compound complies with the
obligations of this Agreement. METABOLEX may reject any such Compound shipment (or portion thereof) if the same does not comply with the requirements as set forth in the Manufacturing Plan or the terms of this Agreement by providing to SIEGFRIED a
written rejection within [*] calendar days from receipt thereof, which rejection identifies the basis for such rejection. METABOLEX shall not have the obligation to pay for any Compound properly rejected. Further, METABOLEX shall have the right to
review the Services performed and/or Deliverables delivered to METABOLEX under a Project, or any portion thereof, and METABOLEX shall not have any obligation to make payments for any such 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 6 

	 	
Services or Deliverables that do not comply with the terms of the applicable Plan, unless and until SIEGFRIED provides to METABOLEX replacement Services or Deliverables (as applicable) that
conform to the criteria in the Plan. If METABOLEX does not reject in writing within [*] calendar days of receipt, [*]. METABOLEX shall clearly state in writing the reasons for any rejection. If SIEGFRIED disagrees with METABOLEX, it shall notify
METABOLEX to such effect, stating the basis of its disagreement, within the [*] days following METABOLEX’s rejection notice. In such event, either Party may elect to have the disagreement resolved by an independent laboratory, whose decision
will be binding on the Parties and whose expenses will be borne by the Party whose position is not upheld by the laboratory. If SIEGFRIED does not dispute METABOLEX’s rejection notice, it shall, within [*] days of such notice present a
corrective plan of action to METABOLEX. Upon approval by METABOLEX of the corrective plan, SIEGFRIED, at no additional expense to METABOLEX (other than paying the payment amounts owed under the applicable Plan, at such time as SIEGFRIED delivers the
conforming Compound, Services or Deliverable (as applicable)), shall then make the corrections and, where applicable, SIEGFRIED shall resubmit the corrected Service or Deliverable to METABOLEX. 

 

	 	3.5.	Disputed Amounts. For disputed invoices or the disputed portion of an invoice, METABOLEX shall provide to SIEGFRIED, in writing, within [*] calendar days of receipt of the invoice, a description of the disputed
amounts and the basis of the dispute. Without limiting either Party’s rights or remedies under law, METABOLEX and SIEGFRIED shall negotiate in a good faith, reasonable manner to resolve any such billing issue or disputed invoice.

  

	4.	TERM, TERMINATION AND RENEWAL 

  

	 	4.1.	Term. This Agreement shall commence on the Effective Date and shall expire five years from the Effective Date unless earlier terminated pursuant to this Article 4 or as otherwise provided for in this Agreement.

  

	 	4.2.	Termination Without Cause. METABOLEX may, at its sole discretion, terminate this Agreement or any Plan without cause on [*] calendar days written notice to SIEGFRIED. ). If METABOLEX terminates this Agreement
(but not any ongoing Plan) pursuant to this Section, such termination shall not terminate the ongoing Plan. Notwithstanding any termination of this Agreement and/or a Plan, the accrued rights of METABOLEX and/or SIEGFRIED pursuant to this Agreement
shall survive. 

  

	 	4.3.	Termination for Discontinuance or Divestiture. SIEGFRIED shall have the right to terminate this Agreement on [*] calendar days written notice to METABOLEX in the event that METABOLEX discontinues all of its
business activities relating to development or commercialization of a Compound covered by this Agreement. 

  

	 	4.4.	Termination For Cause. Either Party shall have the right to terminate this Agreement with immediate effect upon written notice if the other Party materially breaches this Agreement and such breaching Party fails
to cure such breach within [*] calendar days following written receipt of such notice from the non-breaching party specifying such breach and the steps the breaching Party must take in order to remedy such breach. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 7 

	 	4.5.	Termination in Event of Insolvency. In the event that either Party: (i) institutes or has instituted against it a petition for bankruptcy or is adjudicated bankrupt; or (ii) executes a bill of sale,
deed of trust, or a general assignment for the benefit of creditors; or (iii) is dissolved or transfers a substantially all of its assets to a third party receiver or creditor in connection with its insolvency; or (iv) a receiver is
appointed for the benefit of its creditors, or a receiver is appointed on account of insolvency; then the bankrupt Party shall immediately notify the other Party of such event and such other Party shall be entitled to: (a) terminate this
Agreement with immediate effect upon written notice to the insolvent Party; or (b) request that the insolvent Party or its successor provide adequate assurances of continued and future performance in form and substance acceptable to such other
Party, which shall be provided by the insolvent Party within [*] calendar days of such request, and the other Party may terminate this Agreement with immediate effect upon written notice to the bankrupt Party in the event that the Party fails to
provide such assurances acceptable to the other Party within such [*] day period. Termination pursuant to this Section 4.6 shall be without prejudice to any rights and claims accrued under this Agreement or any Plan prior to the termination of
this Agreement. 

  

	 	4.6.	Accrued Claims. The termination or expiry of this Agreement for any reason whatsoever shall be without prejudice for any claims accrued under this Agreement prior to the effectiveness of the expiry or
termination. Without limiting the generality of the foregoing, in the event of the termination or expiry of this Agreement for any reason, METABOLEX shall pay to SIEGFRIED within the [*] calendar days following the effective date of termination or
expiry all payment amounts actually accrued under Section 3.1 under the applicable Plan(s) being terminated, and also shall pay SIEGFRIED’s actual Expenses (based on invoices demonstrating the costs and the basis therefore) that are
incurred in performing the terminated Plan(s) through the termination (above and beyond the costs that are covered by payment amounts already accrued) [*]. 

  

	5.	OWNERSHIP 

  

	 	5.1.	Ownership and Disclosure. METABOLEX shall own all rights, title and interest in and to: (i) all the Deliverables and all Intellectual Property rights and know-how comprising, covering or appurtenant to the
Deliverables; (ii) all Data, other Information and other Intellectual Property that is made, discovered or developed based on or as the direct result of SIEGFRIED’s performance of the Services or other activities under this Agreement, and
(iii) the Compound supplied to METABOLEX hereunder, all Certificates of Analysis, all Data, and all reports and biological or chemical specimens generated by SIEGFRIED as a direct result of conducting the Services (collectively, the
“Project IP”). For the avoidance of doubt, Project IP shall not include any Siegfried Background IP (as defined below) or any Intellectual Property rights, know-how, Information, developed by SIEGFRIED independent of this
Agreement[*]. SIEGFRIED shall notify METABOLEX in writing of any and all Project IP as soon as commercially reasonable after each such conception, reduction to practice, making, or development thereof. 

 

	 	5.2.	Assignment. SIEGFRIED hereby assigns and agrees to assign and transfers to METABOLEX all rights, title and interest in and to all the Project IP. SIEGFRIED agrees to take all further acts reasonably required to
evidence and/or effect or perfect such assignments and transfers to METABOLEX, at METABOLEX’s expense. SIEGFRIED shall enter into an agreement with each employee, agent or consultant of SIEGFRIED performing work in connection with the Services,
pursuant to which such person shall grant all rights in Project IP to SIEGFRIED such that SIEGFRIED may assign and transfer such rights to METABOLEX in accordance with this Section 5.2. SIEGFRIED hereby appoints METABOLEX as its
attorney-in-fact to sign such documents as 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 8 

	 	
METABOLEX deems necessary for METABOLEX to obtain ownership and to apply for, secure, and maintain patent or other proprietary protection of Project IP if METABOLEX is unable, after reasonable
inquiry, to obtain SIEGFRIED’s (or its employee’s , agent’s or consultant’s) signature on such a document(s). METABOLEX shall have the sole right and authority, at its discretion and expense, to prepare, file, prosecute and
maintain any patent applications and patents claiming the Project IP. All Project IP shall be deemed to be and treated as METABOLEX Confidential Information and shall be subject to the confidentiality obligations and provisions of Article 7.

  

	 	5.3.	METABOLEX Property. Subject to the license set forth in Section 5.6, METABOLEX shall retain exclusively all rights, title and interest in and to (i) all Intellectual Property owned or known by METABOLEX
or its agents prior to the Effective Date or made or acquired by METABOLEX during the term of this Agreement, and (ii) all physical property provided to SIEGFRIED in connection with this Agreement. 

 

	 	5.4.	SIEGFRIED Intellectual Property. Subject to the license set forth in Section 5.5, SIEGFRIED shall retain all right, title and interest in and to (i) all Intellectual Property, know-how, information, and
documents (x) owned or known by SIEGFRIED, its agents and Affiliates prior to the Effective Date or (y) made by SIEGFRIED during the term of this Agreement independently of this Agreement [*]. All such Intellectual Property, and all
Intellectual Property otherwise Controlled by SIEGFRIED as of the Effective Date or independently of this Agreement during the term of this Agreement, shall be the “SIEGFRIED Background IP”. 

 

	 	5.5.	License to METABOLEX. [*] a non-exclusive license under any item(s) of SIEGFRIED Background IP [*] (i) to fully exploit any product or service based on, embodying, incorporating, or derived from the
Deliverables; (ii) to exercise any and all other present or future rights in the Deliverables for any and all purposes, or (iii) to manufacture Compound, to manufacture or have manufactured Compound (or any analog or derivative thereof)
for all purposes, including making commercial products, [*]. 

  

	 	5.6.	License to SIEGFRIED. METABOLEX hereby grants to SIEGFRIED for the term of this Agreement a nonexclusive, royalty-free, revocable, right and license (without any rights to sublicense) under Metabolex’s
Intellectual Property, know-how or Information solely to the extent necessary to enable SIEGFRIED to perform Services. SIEGFRIED shall not acquire any other right, title or interest in or to such Intellectual Property as a result of its performance
hereunder. 

  

	6.	DELIVERABLES AND RECORDS 

  

	 	6.1.	Deliverables. SIEGFRIED agrees to provide to METABOLEX (i) all batches of Compound that SIEGFRIED manufactures under this Agreement; (ii) a detailed description of the process used to make each batch of
Compound (each batch Compound will be identified by an internal SIEGFRIED lot number, with a cross-reference to the identification number for the intermediates in the synthetic process and Raw Materials utilized in the synthesis), including
SIEGFRIED’s “batch record”; and (iii) for each batch shipped, a quality statement certifying whether or not the Compound was processed according to cGMPs (Certificate of Compliance) and a Certificate of Analysis that confirms the
Compound meets the Compound Specifications. SIEGFRIED shall also conduct all quality testing provided for in the Plan and the Quality Agreement and provide to METABOLEX all documentation of such quality testing required by the Quality Agreement
and/or the applicable Plan. METABOLEX has responsibility for Compound release (see Section 8.2.2.1). 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 9 

 SIEGFRIED shall deliver to METABOLEX various samples of Compound according to any schedule set
forth in a Plan or as otherwise mutually agreed upon in writing by the Parties. 
  

	 	6.2.	Books and Records. SIEGFRIED shall keep complete and accurate books and records related to all Services performed under the Agreement, including covering the manufacture, processing and supply of the Compound.
SIEGFRIED shall also maintain complete, accurate, and authentic documentation, notes, data, test results, records, master batch records, and working batch records for each batch of Compound, for all Services, and for all other work relating to
Compound and/or any of the Services generated by SIEGFRIED during the performance of, and in connection with, the Plan(s) (collectively, the “Data”). SIEGFRIED shall retain such records for a period of [*] years following the date
of manufacture or for such longer period as may be required by the Quality Agreement, the applicable Plan or Applicable Law. Such records shall be made available to METABOLEX for inspection, copying and/or audit verification by METABOLEX or its
designee at any reasonable time during SIEGFRIED regular business hours. Upon METABOLEX’s request, SIEGFRIED shall make copies of such records available to METABOLEX, at METABOLEX’ expense. 

 

	7.	USE OF CONFIDENTIAL INFORMATION 

  

	 	7.1.	Each Party agrees to maintain in strict trust and confidence and shall not disclose to any Third Party any Confidential Information of the other Party, and shall not use any such Confidential Information of the
other Party for any purpose, either for itself or for a Third Party, other than as provided for in this Agreement. 

  

	 	7.2.	Each Party agrees that it will disclose the Confidential Information of the other Party only to such of its officers, employees and approved subcontractors (“Representatives”) who are directly
concerned with performance of the work or exercise of rights granted hereunder, and only after such Representatives have been advised of the confidential nature of such information and are bound by obligations of confidentiality with respect to such
Confidential Information that are substantially similar to the terms of this Agreement. The Party having such obligations (the “Receiving Party”) as to the Confidential Information of the other Party shall be liable for any failure
of any of its Representatives to (i) maintain the confidentiality of such Confidential Information, or (ii) otherwise comply with the terms of this Agreement to the same extent as the Receiving Party is obligated to do so.

  

	 	7.3.	The preceding obligations on a Party to maintain the Confidential Information of the other Party in confidence and the limitation upon the right to use such Confidential Information shall not apply to specific
Confidential Information to the extent such Party can demonstrate with competent evidence that: (i) such Confidential Information disclosed by the other Party (the “Disclosing Party”) to such Party pursuant to this Agreement
was already in Receiving Party’s possession at the time of disclosure by the Disclosing Party; or (ii) such Confidential Information is or becomes in the future public knowledge through no fault or omission by the Receiving Party;
(iii) such Confidential Information is obtained by Receiving Party from a Third Party with a legal right to disclose and not under a confidentiality obligation to the Disclosing Party; or (iv) is independently developed by the Receiving
Party without use of any Confidential Information of the Disclosing Party, as demonstrated by the Receiving Party’s independent written records contemporaneous with such development. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 10 

	 	7.4.	The preceding obligations to maintain in confidence and the limitations upon the right to use the Confidential Information received pursuant hereto, shall terminate [*] years from termination or expiry of this
Agreement. 

  

	 	7.5.	SIEGFRIED agrees to use Raw Materials and Compound only for the performance of Services and under the terms and conditions of this Agreement. 

 

	 	7.6.	Notwithstanding any other provision of this Agreement, the Receiving Party may disclose specific Confidential Information of the other Party to the extent that such disclosure: (i) is in response to a valid
order of a court or other governmental body having jurisdiction or (ii) is otherwise required by applicable law or regulation, provided in either case that Receiving Party uses best efforts to limit the scope of the disclosure to that which is
required, provides Disclosing Party with prior written notice of such requirement as soon as reasonably possible, and cooperates with Disclosing Party in seeking a protective order, confidential treatment, or similar remedy limiting the use and
disclosure of any Information required to be disclosed. 

  

	 	7.7.	Neither Party shall disclose to the other Party any confidential or proprietary information that belongs to any Third Party unless the Disclosing Party first obtains the consent of such Third Party to such
disclosure. 

  

	 	7.8.	Notwithstanding the foregoing, either Party may disclose the text and terms of this Agreement in filings with the United States Securities and Exchange Commission or any other governmental body (U.S. and
otherwise) to the extent such disclosure is required by Applicable Law, as well as in disclosures in confidence to its auditors and attorneys. In addition, METABOLEX may disclose the text and terms of this Agreement in confidence in disclosures to
its investors, and strategic partners, and to potential investors, acquirors, and strategic partners. SIEGFRIED may disclose the text and terms of this Agreement (but not Plans) in confidence in disclosures to its investors, and strategic partners,
and to potential investors, acquirors, and strategic partners. 

  

	8.	FACILITY AND COMPOUND REQUIREMENTS 

  

	 	8.1.	Facility 

  

	 	8.1.1.	In performing the Services, SIEGFRIED shall comply with all Applicable Laws for a drug establishment and obtain and maintain all necessary registrations, licenses and permits. METABOLEX shall have the right to
review, from time to time as it requests, during normal business hours, and upon written notice of no less than [*], each registrations, licenses and permits of SIEGFRIED that is directly related to SIEGFRIED’s obligations under this Agreement,
including but not limited to those required by the FDA or any other regulatory agency having jurisdiction over SIEGFRIED. 

  

	 	8.1.2.	For Services under a Manufacturing Plan, SIEGFRIED shall ensure that the facility meets all the requirements of a drug establishment promulgated by the FDA at all times during the manufacture of the Compound, and
SIEGFRIED shall comply with all aspects required by the Quality Agreement. 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 11 

	 	8.1.3.	SIEGFRIED shall promptly notify METABOLEX of any FDA or other regulatory audit or inspection that is directly relevant to the Services or facilities used in performing the Services. SIEGFRIED shall promptly
provide to METABOLEX a copy of all correspondence and reports that it receives from a governmental agency or regulatory authority in connection with the Services or its manufacture of Compound. SIEGFRIED shall take all reasonable actions requested
by FDA or another governmental agency or regulatory authority to cure deficiencies as noted during any such inspection. METABOLEX shall [*] notify SIEGFRIED of any activities or communications by METABOLEX that may reasonably be expected to result
in an inspection of SIEGFRIED. METABOLEX’S involvement in such audit or inspection shall [*]. 

  

	 	8.2.	Authority and Compound Requirements 

  

	 	8.2.1.	Each Party represents and warrants to the other that, to its current knowledge, (i) it has the full right and authority to enter into and to perform its obligations under this Agreement, (ii) this
Agreement has been duly authorized and (iii) this Agreement is binding upon it. 

  

	 	8.2.2.	METABOLEX and SIEGFRIED hereby agree that with respect to the Services and the Compound, and in addition to the other rights and obligations of this Agreement they each have the following responsibilities and
liabilities: 

  

	 	8.2.2.1.	METABOLEX shall ensure that [*] relating to Compound manufactured hereunder will [*] under this Agreement as required by Applicable Law and will comply with all regulation for governmental applications, submissions, and
approvals. METABOLEX further represents, warrants and covenants that no Compound will be released for human public use or consumption until all requisite governmental approvals thereof have been obtained for such use and consumption.

  

	 	8.2.2.2.	SIEGFRIED will make its own identification tests on the Raw Materials delivered to SIEGFRIED before commencing manufacture of the Compound (and shall not commence manufacture if such tests indicate the Raw Materials do
not comply with the applicable specifications). 

  

	 	8.2.2.3.	SIEGFRIED shall be responsible for manufacturing, storing, handling, and shipping the Compound in accordance with the specifications provided to SIEGFRIED and the agreed upon terms in the relevant Plan.

  

	 	8.2.2.4.	METABOLEX and SIEGFRIED (except where METABOLEX has the responsibility under Section 8.2) shall comply with all Applicable Law, rules, regulations, codes, and standards of all federal, state, local and
municipal government agencies that affect their respective performance and activities under this Agreement. Each Party shall provide upon request such information as the other Party reasonably requires for compliance with all Applicable Law, rules,
regulations, codes, and standards of all federal, state, local and municipal government agencies that affect their respective performance and activities under this Agreement. 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 12 

	 	8.2.2.5.	During all periods when any Raw Materials, Compound or other property of METABOLEX, is stored on the premises of SIEGFRIED, SIEGFRIED shall be responsible for all insurable risks of loss or damage to such stored
Raw Materials, Compound, or property. SIEGFRIED shall not be responsible for risk of loss of any Raw Material or Compound not stored on the premises of SIEGFRIED. 

 

	 	8.2.2.6.	Except as provided below, SIEGFRIED and METABOLEX shall maintain, throughout the term of this Agreement (and, with respect to any policies made on a “claims made” basis, after the term hereof for at least [*]
years following the performance of the Services such liability insurance as is reasonably requested by SIEGFRIED and METABOLEX, respectively, from time to time and in the amounts of not less than USD [*] in the aggregate, and will cause the other
Party to be named as an additional insured thereunder, and to be covered with respect to the contractual indemnities hereunder, without liability for premiums. Each Party shall submit certificates of insurance, evidencing such insurance coverage,
when requested by the other Party. SIEGFRIED further agrees to maintain workers’ compensation insurance in the amount required by the laws of the state in which SIEGFRIED’s employees performing the Services are located. 

 

	 	8.2.3.	No Debarred Person. SIEGFRIED represents and warrants that it shall not employ, contract with, or retain any person directly or indirectly to perform the Services under this Agreement [*] under investigation by
the FDA for debarment or being presently debarred by the FDA pursuant to the Generic Drug Enforcement Act of 1992, as amended (21 U.S.C. § 301, et seq.). In addition, SIEGFRIED represents and warrants that, to its best knowledge, it has
not engaged in any conduct or activity that could lead to any such debarment actions. If during the term of this Agreement, SIEGFRIED [*] (i) coming under investigation by the FDA for a debarment action, (ii) being debarred, or
(iii) engaging in any conduct or activity that could lead to debarment, SIEGFRIED shall immediately notify METABOLEX of same, subject to limitations and disclosure prohibitions pursuant to Applicable Laws, including but not limited to data
protection laws. 

  

	 	8.2.4.	No Pending Regulatory Actions. SIEGFRIED represents and warrants that, as of the Effective Date, it has not received any citations with respect to its manufacturing facilities, including without limitation FDA
Form 483 warning letters, and is not currently subject to an FDA consent decree or other regulatory action impacting SIEGFRIED’s manufacture of Compound under this Agreement. 

 

	 	8.2.5.	No Pending Litigation. SIEGFRIED represents and warrants that, as of the Effective Date, it is not currently involved in any litigation, and is unaware of any pending litigation proceedings, relating to
SIEGFRIED’s performance of services for any Third Party that could materially affect SIEGFRIED’s performance of its obligations under this Agreement. 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 13 

	 	8.2.6.	Shipping. SIEGFRIED will package, insure and ship the Compound in accordance with the instructions stated in the applicable Plan. METABOLEX will be responsible for providing instructions for and payment of
freight, insurance, customs duties and related charges for delivery of packaged Compounds to METABOLEX incurred after title passes to METABOLEX, unless otherwise specified in the applicable Plan, and SIEGFRIED shall comply with METABOLEX’s
instructions. 

  

	 	8.2.7.	No Infringement. SIEGFRIED represents and warrants that no Siegfried Background IP, when used as contemplated in this Agreement, will infringe or misappropriate, any intellectual property right of any Third
Party. METABOLEX represents and warrants that no METABOLEX Intellectual Property, know-how or Information that is licensed to SIEGFRIED pursuant to Section 5.6 will infringe or misappropriate any intellectual property right of any Third Party
when used as permitted in this Agreement. 

  

	 	8.2.8.	SIEGFRIED Indemnification. METABOLEX shall indemnify, defend, and hold harmless SIEGFRIED and SIEGFRIED’s directors, officers, employees, Affiliates and agents (the “SIEGFRIED
Indemnitees”) from and against any and all liabilities, losses, judgments, costs and expenses (including reasonable attorneys’ fees and legal expenses) (collectively, “Losses”) that are based on or caused by any
allegations, claims, suits, or action by a Third Party (collectively “Claims”) against any SIEGFRIED Indemnitee to the extent such Claims result from or arise out of: (i) gross negligence, recklessness or intentional misconduct
on the part of METABOLEX or its directors, officers, employees or agents; or (ii) a breach of METABOLEX’s obligations, covenants, representations, or warranties under this Agreement (each, a “METABOLEX Assumed Liability”).
Such indemnity shall not apply to the extent that a Claim arises out of or results from a SIEGFRIED Assumed Liability (as defined in Section 8.2.9). 

  

	 	8.2.9.	METABOLEX Indemnification. SIEGFRIED shall indemnify, defend, and hold harmless METABOLEX and METABOLEX’s directors, officers, employees, Affiliates and agents (the “METABOLEX Indemnitees”)
from and against any and all Losses that are based on or caused by any Claims against any METABOLEX Indemnitee to the extent such Claims result from or arise out of: (i) gross negligence, recklessness or intentional misconduct on the part of
any one of the SIEGFRIED Indemnitees, (ii) a failure of any one of the SIEGFRIED Indemnitees to comply with any Applicable Law in the performance of the work under this Agreement, or (iii) a breach of SIEGFRIED’s obligations,
covenants, representations, or warranties under this Agreement or Compound (each, a “SIEGFRIED Assumed Liability”). Such indemnity shall not apply to the extent that a Claim arises out of or results from any METABOLEX Assumed
Liability. 

  

	 	8.2.10.	Indemnification Procedure. In the event that any Claim is asserted or imposed against any Party hereto, then such Party (an “Indemnified Party”) shall promptly give written notice to the other
Party (the “Indemnifying Party”) of such Claim. The Indemnified Party shall take all reasonable measures to limit or mitigate any Losses and shall inform the Indemnifying Party of all such measures. The Indemnifying Party shall
assume, at its cost and expense, the defense of such Claim. The Indemnifying Party shall have control over the Claim, including the right to settle; provided, however, that the Indemnifying Party shall not, absent the prior written consent of the
Indemnified Party, consent to the entry of any judgment or enter into any settlement that (i) provides for any relief other than the payment of monetary damages for which the Indemnifying Party shall be 

 
 [*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 14 

	 	
solely liable and (ii) where the claimant or plaintiff does not release the Indemnified Party, its Affiliates and its respective directors, officers, employees, agents and representatives,
as the case may be, from all liability in respect thereof. In no event shall the Indemnified Party be liable for any claims that are compromised or settled in violation of this Section. 

 

	 	8.2.11.	Except for Losses resulting from SIEGFRIED’s gross negligence, fraud or willful misconduct, in no event shall SIEGFRIED’s total liability to METABOLEX arising under this Agreement exceed the total amount paid
by METABOLEX to SIEGFRIED for the Services. Except for Losses resulting from METABOLEX’s gross negligence, fraud or willful misconduct, in no event shall METABOLEX’s total liability to SIEGFRIED arising under this Agreement exceed the
total amount paid (or owed hereunder) by METABOLEX to SIEGFRIED for the Services. The above terms of this Section 8.2.11 shall not be deemed to limit a Party’s obligations under section 8.2.8 or 8.2.9, or a Party’s liability for a
breach of its obligations under Article 7. 

  

	9.	SURVIVAL 

 The termination of this Agreement shall not affect the provisions of Sections 1, 5, 7, 8.2.8,
8.2.9, 8.2.10, 8.2.11, 9, 10, 13.1, 13.2, 13.3, 13.4, and 13.14, which shall expressly survive any termination. 
  

	10.	PRESS RELEASE 

 No Party shall (i) issue a press release or make any other public statement that
references this Agreement, or (ii) use the other Party’s or its Affiliates’ name or trademarks for publicity or advertising purposes, except, in each case, with the prior written consent of the other Party. For the avoidance of doubt,
SIEGFRIED shall not disclose, present, disseminate or produce any publication that contains information regarding the Services, Deliverables or any Confidential Information of METABOLEX without METABOLEX’s prior written consent. Notwithstanding
the foregoing sentences, either Party may use the name of the other Party in regulatory filings, including filings with the FDA and the United States Securities and Exchange Commission, or in disclosures to investors, partners, potential investors,
and potential partners. For the avoidance of doubt, each Party shall fully comply with Section 7 when issuing a press release or making any other public statement. 
  

	11.	EFFECT OF OTHER AGREEMENTS 

 This Agreement, together with validly approved Plans, sets forth the entire
agreement between SIEGFRIED and METABOLEX as to their subject matter and supersedes all other agreements and understandings between the Parties with respect to the same. 
  

	12.	ACCESS TO SITE 

  

	 	12.1.	METABOLEX personnel will be afforded reasonable access to the SIEGFRIED site on advance written notice of not less than two weeks and during regular working hours or any other time during which work under any Plan is
being performed. SIEGFRIED will use its best efforts to accommodate any requests for visitations during such periods. 

  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 15 

	 	12.2.	While on site, METABOLEX personnel will use best care in the conduct of their activities. METABOLEX will indemnify and otherwise hold SIEGFRIED harmless from any damages resulting from violation of this due care
standard by METABOLEX personnel. 

  

	13.	MISCELLANEOUS 

  

	 	13.1.	Notices. All notices, consents and approvals required or permitted hereunder shall be given in writing to the other Party by personal delivery, by certified or registered mail, return receipt requested, by
overnight courier, or by facsimile transmission with electronic confirmation of transmission, at the address specified below or to such other addresses as may be designated in writing from time to time in accordance with this Section 13.1:

  

							
		  	If to METABOLEX:	  	METABOLEX, Inc.	  	
		  		  	3876 Bay Center Place	  	
		  		  	Hayward, CA 94545	  	
		  		  	Attention: Legal Department	  	
		  		  	Fax (510) 293-9090	  	
				
		  	For SIEGFRIED:	  	SIEGFRIED AG	  	
		  		  	Untere Brühlstrasse 4	  	
		  		  	Zofingen CH4800	  	
		  		  	Switzerland	  	
		  		  	Attention: Legal Department	  	
		  		  	Fax +41 62 746 1507	  	

  

	 	13.2.	LIMITATION OF DAMAGES. NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT TO THE CONTRARY, IN NO EVENT SHALL SIEGFRIED OR METABOLEX BE LIABLE TO THE OTHER FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE,
MULTIPLE-BASED OR CONSEQUENTIAL DAMAGES (INCLUDING LOSS OF REVENUES OR PROFIT TO A PARTY OR A THIRD PARTY) ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, OR OTHERWISE, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT
THAT THE FOREGOING SHALL NOT LIMIT DAMAGES FOR BREACH OF THE OBLIGATIONS IN ARTICLE 7. FURTHER, THE ABOVE TERMS OF THIS SECTION 13.2 SHALL NOT BE DEEMED TO LIMIT A PARTY’S OBLIGATIONS UNDER SECTION 8.2.8 OR 8.2.9. 

 

	 	13.3.	Governing Law. Any claim, dispute, or controversy of whatever nature arising out of or relating to this Agreement shall be governed by and construed in accordance with the laws of the State of New York, without
giving effect to any choice of law principles that would require the application of the laws of a different state. 

  

	 	13.4.	Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. 

 

	 	13.5.	Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original. Copies of original signature pages sent by facsimile and/or PDF shall have the
same effect as signature pages containing original signatures. 

  
 [*]
= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 16 

	 	13.6.	Amendment, Waiver. This Agreement may be amended, modified, superseded or canceled, and any of the terms may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party
or Parties waiving compliance. The delay or failure of any Party at any time or times to require performance of any provisions shall in no manner affect the rights at a later time to enforce the same. No waiver by any Party of any condition or of
the breach of any term contained in this agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any
other term of this Agreement. 

  

	 	13.7.	No Third Party Beneficiaries. No Third Party, including any employee of any Party to this Agreement, shall have or acquire any rights by reason of this Agreement. 

 

	 	13.8.	Assignment and Successors. This Agreement may not be assigned by either Party, except that each Party may assign this Agreement and the rights and interests of such Party, in whole or in part, to any of its
Affiliates, any purchaser of all or substantially all of its assets or to any successor corporation resulting from any merger or consolidation of such Party with or into such corporation. 

 

	 	13.9.	Force Majeure. Neither METABOLEX nor SIEGFRIED shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such
failure or delay is due to natural disasters or any causes reasonably beyond the control of METABOLEX or SIEGFRIED, as applicable. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical
and shall take reasonable, diligent efforts to remove the condition constituting force majeure or to avoid its affects so as to resume performance as soon as practicable. 

 

	 	13.10.	Severability. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the Parties that the remainder
of the Agreement shall not be affected. The Parties shall make a good faith effort to replace any such provision with a valid and enforceable one such that the objectives contemplated by the parties when entering this Agreement may be realized.

  

	 	13.11.	Employees. Each Party shall be responsible for claims made by its own employees, and each Party shall defend, indemnify and hold harmless the other Party, the other Party’s employees, directors, trustees and
officers, from and against any and all liability, claims, damages, losses, actions or suits, which the other Party may incur by reason of any claim made by an employee of the Party, except for injuries resulting from the gross negligence or willful
misconduct of the other Party. 

  

	 	13.12.	Relationship of Parties. The relationship between the Parties is that of independent contractors. Neither Party, nor any employee or agent of such Party, shall have the authority to bind or act on behalf of the
other Party without its prior written consent. No employee or agent of SIEGFRIED shall be considered to be an employee or agent of METABOLEX, and no employee or agent of METABOLEX shall be considered to be an employee or agent of SIEGFRIED. Each
Party shall be solely and entirely responsible for its acts and for the acts of its employees and agents during performance of this Agreement. This Agreement shall not constitute, create, or in any way be interpreted as a joint venture, partnership
or business organization of any kind. 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 17 

	 	13.13.	Construction. Section headings are included in this Agreement merely for convenience of reference; they are not to be considered part of this Agreement or used in the interpretation of this Agreement. No rule of
strict construction will be applied in the interpretation or construction of this Agreement. 

  

	 	13.14.	Time Is of the Essence. Time is of the essence in the performance of the Services and SIEGFRIED’s other obligations under this Agreement. 

[Remainder of page intentionally left blank] 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 18 

 In witness whereof, the parties hereto have duly executed this Agreement as of the Effective Date. 

 

									
	METABOLEX, INC.	 		 	SIEGFRIED AG
					
	By:	 	 /s/ Charles A. McWherter
	 		 	By:	 	 /s/ Marianne Spaene

			
	 Charles A. McWherter
	 		 	 Marianne Spaene

	Print Name	 		 	Print Name
			
	 SVP, Research and Preclinical Dev’t
	 		 	 EVP Business Dev

	Title	 		 	Title
				
		 		 	By:	 	 /s/ Sandra Cernick

			
		 		 	 Sandra Cernick

		 		 	Print Name
			
		 		 	Senior Director
		 		 	 Business Development & Sales USA

		 		 	Title

  
 [*] = Certain confidential information contained in
this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 19 

 Exhibit A 

Compound & Raw Materials 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 20 

 Exhibit B 

Process Development Plan 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 21 

 Exhibit C 

Manufacturing Plan 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 22 

 Exhibit D 

Form of Scope of Work 

Scope of Work No. __ 

THIS SCOPE OF WORK NO.
             (a “Scope of Work”) is made and entered into as of             
    , 20    , by and between METABOLEX, INC. a Delaware corporation with a business address of 3876 Bay Center Place, Hayward, California 94545 (“METABOLEX”) SIEGFRIED AG,
a Swiss Company, with its principal address place of business located at Untere Brühlstrasse 4, Zofingen CH4800 Switzerland (“SIEGFRIED”). 

Pursuant to the terms and conditions of the Development and Clinical Manufacture Agreement of
             (the “Master Agreement”), SIEGFRIED has agreed to perform certain services in accordance with written Scopes of Work, such as this one, entered into
from time-to-time. 
 The parties hereby agree as follows: 

1. Scope of Work. This document constitutes a “Scope of Work” under the Master Agreement, and this Scope of Work and the work
contemplated herein are subject to the terms and provisions of the Master Agreement. 
 2. Services and Payment of Fees and Expenses.
The specific work contemplated by this Scope of Work and the related payment terms and obligations are set forth on the following attachments, which are incorporated herein by reference: 

 

			
	DESCRIPTION OF WORK	  	ATTACHMENT 1
	PROJECT BUDGET	  	ATTACHMENT 1
	TIMELINE	  	ATTACHMENT 1
	PAYMENT SCHEDULE	  	ATTACHMENT 1

 3. Term. The term of this Scope of Work shall commence on
                 , 20     and shall continue until the services described in Attachment 1 are completed, unless this
Scope of Work is terminated in accordance with the Master Agreement, and except as otherwise provided for in this Agreement. 
 4.
Amendments. No modification, amendment, or waiver of this Scope of Work shall be effective unless in writing and duly executed and delivered by each Party to the other. 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 23 

 Exhibit D, continued 

ACKNOWLEDGED, ACCEPTED AND AGREED TO: 

EXAMPLE ONLY – NOT FOR SIGNATURE 
  

									
	METABOLEX, INC.	 		 	SIEGFRIED AG
					
	By:	 	 	 		 	By:	 	 
			
	  
	 		 	  

	Print Name	 		 	Print Name
			
	  
	 		 	  

	Title	 		 	Title
				
		 		 	By:	 	 
			
		 		 	  

		 		 	Print Name
			
		 		 	  

		 		 	Title

 1169616 v5/HN 
  

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 24EX-10.1

 Exhibit 10.1 

H&R BLOCK, INC. EXECUTIVE SEVERANCE PLAN 

(Amended and Restated effective November 8, 2013) 

The H&R Block, Inc. Executive Severance Plan was adopted by H&R Block, Inc., a Missouri corporation (“HRB”) effective as of
May 12, 2009. This amendment and restatement is effective November 8, 2013 (as so amended and restated, the “Plan”). 

Section 1. Purpose 

The Company considers the establishment and maintenance of a sound and vital management to be essential to protecting and enhancing the best
interests of the Company and its shareholders. This Plan provides severance pay to compensate management for the involuntary loss of employment and a period of readjustment. The Company also recognizes that a Change in Control of HRB may arise in
the future and that such event may result in the departure or distraction of management to the detriment of the Company and its shareholders. Accordingly, the Board has determined it is in the best interests of the Company and its shareholders to
secure the continued services and dedication of such management in the event of any threat or occurrence of a Change in Control of HRB by providing such management the benefits set forth in this Plan. 

This Plan supersedes all prior agreements, arrangements or plans of the Company related to separation pay in the event of a Qualifying
Termination or Change in Control Termination, except as provided in the following sentence. Notwithstanding the foregoing, nothing under this Plan supersedes or replaces (a) any rights to acceleration of vesting granted to a Participant under
the H&R Block, Inc. 2003 Long-Term Executive Compensation Plan to the extent such rights are greater than those granted under this Plan, (b) any rights granted to a Participant under the H&R Block, Inc. 2013 Long Term Incentive Plan, or
any successor plan, for grants on or after March 5, 2013, or (c) any previously granted rights to non-exempt nonqualified deferred compensation subject to Section 409A (as defined in Section 11 of this Plan), unless the rights
under this Plan are exempt from Section 409A or this Plan’s payment provisions satisfy the subsequent deferral rules promulgated pursuant to Section 409A. Any benefits conferred under this Plan will be provided to Participants in lieu
of benefits under any other severance plan. 
 Section 2. Definitions 

For purposes of this Plan, the following terms shall have the meanings specified below unless the context clearly requires otherwise: 

 

	 	(a)	“Affiliate” shall have the meaning ascribed to such term in Rule 12b-2 of Regulation 12B under the Securities Exchange Act of 1934, as amended. 

 

	 	(b)	“Base Compensation” means a Participant’s annual base salary plus Participant’s annual target short-term incentive opportunity. 

 

	 	(c)	“Board” means the Board of Directors of HRB. 

  

	 	(d)	“Cause” means any of the following unless, if capable of cure, such events are fully corrected in all material respects by Participant within ten (10) days after the Company provides notice of the
occurrence of such event: 

	 	i.	A Participant’s misconduct that materially interferes with or materially prejudices the proper conduct of the business of the Company; 

 

	 	ii.	A Participant’s commission of an act materially and demonstrably detrimental to the good will of the Company; 

  

	 	iii.	A Participant’s commission of any act of dishonesty or breach of trust resulting or intending to result in material personal gain or enrichment of the Participant at the expense of the Company; 

 

	 	iv.	A Participant’s violation of any non-competition, non-solicitation, confidentiality or similar restrictive covenant under any employment-related agreement, plan or policy with respect to which the Participant is a
party or is bound; or 

  

	 	v.	A Participant’s conviction of, or plea of guilty or nolo contendere to, a misdemeanor involving an act of moral turpitude or a felony. 

If the Company does not give the Participant a termination notice within sixty (60) days after the Board or the Chairman of the Board has
knowledge that an event constituting Cause has occurred, the event will no longer constitute Cause. The Company may place a Participant on unpaid leave for up to 30 consecutive days while it is determining whether there is a basis to terminate the
Participant’s employment for Cause. Such unpaid leave will not constitute Good Reason. 
 For purposes of this definition, any act or
omission by the Participant based on authority given pursuant to a resolution duly adopted by the Board will be deemed made in good faith and in the best interests of the Company. 

(e) “Change in Control” means the occurrence of one or more of the following events: 

 

	 	i.	Any one person, or more than one person acting as a group, acquires ownership of stock of HRB that, together with stock held by such person or group, constitutes more than 50 percent of the total fair market value or
total voting power of the stock of HRB. If any one person, or more than one person acting as a group, is considered to own more than 50 percent of the total fair market value or total voting power of the stock of HRB, the acquisition of additional
stock by the same person or persons shall not be considered to cause a Change in Control. An increase in the percentage of stock owned by any one person, or persons acting as a group, as a result of a transaction in which HRB acquires its stock in
exchange for property will be treated as an acquisition of stock for purposes of this Section 2(e)(i). 

  

	 	ii.	Any one person, or more than one person acting as a group, acquires (when combined with all other acquisitions of HRB stock acquired during the twelve (12) month period ending on the date of the most recent
acquisition by such person or persons) ownership of stock of HRB possessing 35 percent or more of the total voting power of the stock of HRB. If any one person, or more than one person acting as a group, is considered to effectively control a
corporation within the meaning of Treasury Regulation §1.409A-3(i)(5)(vi), the acquisition of additional control of the corporation by the same person or persons is not considered to cause a change in the effective control of the corporation.
An increase in the percentage of stock owned by any one person, or persons acting as a group, as a result of a transaction in which HRB acquires its stock in exchange for property will not be treated as an acquisition of stock for purposes of this
Section 2(e)(ii), but will be treated as an acquisition of stock for purposes of Section 2(e)(i). 

  
 2 

	 	iii.	A majority of members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by two-thirds (2/3) of the members of the Board before the date of such
appointment or election. 

  

	 	iv.	Any one person, or more than one person acting as a group, acquires (when combined with all other acquisitions of HRB assets acquired during the twelve (12) month period ending on the date of the most recent
acquisition by such person or persons) assets from HRB that have a total gross fair market value equal to or more than 50 percent of the total gross fair market value of all of the assets of HRB immediately before such acquisition or acquisitions.
For this purpose, gross fair market value means the value of the assets of HRB, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. Notwithstanding the foregoing, there is no Change
in Control event under this Section 2(e)(iv) when there is a transfer to an entity that is controlled by the shareholders of HRB immediately after the transfer. A transfer of assets by HRB is not treated as a change in the ownership of such
assets if the assets are transferred to: (a) a shareholder of HRB (immediately before the asset transfer) in exchange for or with respect to its stock; (b) an entity, 50 percent or more of the total value or voting power of which is owned,
directly or indirectly, by HRB; (c) a person, or more than one person acting as a group, that owns, directly or indirectly, 50 percent or more of the total value or voting power of all the outstanding stock of HRB; or (d) an entity, at
least 50 percent of the total value or voting power of which is owned, directly or indirectly, by a person described in (c) above. 

Notwithstanding the foregoing, the direct or indirect sale of any or all of the stock of, merger or liquidation of, or sale or assumption of
all or substantially all the assets or liabilities of, H&R Block Bank FSB, (x) will not be considered a Change in Control for purposes of this Plan, and (y) will not be included in any determination of the total gross fair market value
of assets of HRB sold during any 12-month period under Section 2(e)(iv) above. 
 For purposes of this section, persons will be
considered to be acting as a group in accordance with Sections 13(d)(3) and 14(d)(2) of the Securities Exchange Act of 1934, as amended, and Section 409A of the Code. 
  

	 	(f)	“Change in Control Termination” means a Participant’s Qualifying Termination or Good Reason Termination, in either event within seventy-five (75) days immediately preceding or within eighteen
(18) months immediately following a Change in Control. 

  

	 	(g)	“COBRA Subsidy” means an amount equal to the Participant’s monthly post-employment premium for health and welfare benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985
(“COBRA”) less the amount paid from time to time by active employees for similar coverage. To be eligible for the COBRA Subsidy, the Participant must be enrolled in the Participating Employer’s health and welfare plans on the date of
Separation from Service. 

  
 3 

	 	(h)	“Code” means the Internal Revenue Code of 1986, as amended. 

  

	 	(i)	“Company” means HRB and its Affiliates. 

  

	 	(j)	“Comparable Position” means a position where: 

 (i) the primary work
location is within 50 miles of the Participant’s primary work location prior to the Qualifying Termination and 
 (ii)
the Base Compensation is not more than 10% below the Participant’s compensation rate at the time of the Qualifying Termination. 
  

	 	(k)	“ERISA” means the Employee Retirement Income Security Act of 1974, as amended. 

  

	 	(l)	“Good Reason Termination” means a Separation from Service: 

 (i) which is initiated by
the Participant within seventy-five (75) days immediately preceding or within eighteen (18) months immediately following a Change in Control on account of one or more of the following conditions occurring within that same time frame: 

(A) A material diminution in the Participant’s Base Compensation; 

(B) A material diminution in the Participant’s authority, duties, or responsibilities; 

(C) A material change in the geographic location at which the Participant must perform the services; or 

(D) Any other action or inaction that constitutes a material breach by the Company of any written employment-related agreement
between the Participant and the Company; 
 (ii) for which the Participant does not consent to the condition referenced in (i) above;
and 
 (iii) for which the Company does not substantially remedy the condition (as described in this section). 

A Participant must provide notice to the Company of the existence of any of the foregoing conditions within thirty (30) days of the later
of (x) initial existence of the condition for which Participant will terminate employment and (y) the date the Change in Control occurs; provided, however, that any notice relating to a condition that initially occurs before such Change in
Control must be provided no later than ninety (90) days following the initial existence of the condition (it being understood that for purposes of both clauses (x) and (y) above, the relevant time period commences as of the date
Participant knows or should reasonably have known of the existence of such condition). Participant must remain employed with the Company for at least thirty (30) days after providing such notice. During the thirty (30) days following
receipt of the notice, the Company may substantially remedy the event, occurrence or condition for which notice was given, in which case a Good Reason Termination will not occur as a result of the condition and the Company will not be required to
pay the amount. 
  

	 	(m)	“HRB” means H&R Block, Inc., a Missouri corporation. 

  

	 	(n)	“Initial Effective Date” means May 12, 2009. 

  
 4 

	 	(o)	“Monthly Compensation” means a Participant’s highest annual base salary as of the Change in Control or during the twelve (12) month period immediately preceding his or her Separation Date divided by
twelve (12). For the avoidance of doubt “annual base salary” does not include bonuses, incentive compensation, or compensation received pursuant to any equity award. 

 

	 	(p)	“Participant” means an associate of the Company whose participation in the Plan is approved by the Compensation Committee of the Board (or other committee appointed by the Board to administer the Plan pursuant
to Section 18). 

  

	 	(q)	“Payment Date” means the date which is the earlier of 

 (i) thirty
(30) days after the Release Date; and 
 (ii) March 15 of the year immediately following the year in which
Participant becomes eligible for payments or benefits under this Plan. 
  

	 	(r)	“Plan” means this H&R Block, Inc. Executive Severance Plan, as amended from time to time. This document serves as both the legal plan document and summary plan description. 

 

	 	(s)	“Plan Administrator” and “Plan Sponsor” means H&R Block Management, LLC. The address and telephone number of H&R Block Management, LLC is One H&R Block Way, Kansas City, Missouri 64105,
(816) 854-3000. 

  

	 	(t)	“Qualifying Termination” means the involuntary Separation from Service by the Company under circumstances not constituting Cause but does not include: 

(i) the elimination of the Participant’s position where the Participant was offered a Comparable Position with the Company
or with a party that acquires any asset from the Company (or a subsidiary or an affiliate of such a party), 
 (ii) the
redefinition of a Participant’s position to a lower compensation rate or grade; or 
 (iii) the Participant’s
Separation from Service due to death or disability. 
  

	 	(u)	“Release Agreement” means the release agreement, substantially in the form set forth as Exhibit A to this Plan, which a Participant shall be required to execute as a condition to receiving payments and
benefits under this Plan. 

  

	 	(v)	“Release Date” means sixty (60) days after a Participant’s Separation Date. 

  

	 	(w)	“Separation Date” means the effective date of a Participant’s Separation from Service. 

  

	 	(x)	“Separation from Service” means the date that a Participant separates from service within the meaning of Section 409A of the Code and Treasury Regulation §1.409A-1(h). 

(y) “Year of Service” means each period of twelve (12) consecutive months of employment measured from the Participant’s
employment commencement date. In determining a Participant’s Years of Service, the Participant will be credited with a partial Year of Service for his or her final period of employment commencing on his or her most recent employment anniversary
date equal to a fraction calculated in accordance with the following formula: 

  
 5 

 (Number of days since most recent employment anniversary date ÷ 365) 

Notwithstanding the foregoing, in no event will a Participant be credited with less than twelve (12) Years of Service or more than
eighteen (18) Years of Service. 
 Section 3. Severance Benefits. 

(a) If a Participant incurs a Qualifying Termination or a Change in Control Termination and executes his or her Release Agreement and returns
it to the Company by the deadline set forth in the Release Agreement, then the Participant shall be entitled to the following compensation and benefits (unless the Participant revokes the Release Agreement during the seven (7) day period
described in the Release Agreement): 
 (i) The Company shall pay the Participant, on the Payment Date, a lump sum severance
amount equal to: 
 (A) the Participant’s Monthly Compensation multiplied by the Participant’s Years of Service;
plus 
 (B) a specified percentage of the Participant’s Monthly Compensation as determined by the Board or the
Compensation Committee (or other committee appointed by the Board to administer the Plan pursuant to Section 18) from time to time, in its sole discretion, multiplied by the Participant’s Years of Service; plus 

(C) an amount equal to the Participant’s COBRA Subsidy multiplied by twelve (12). To be eligible for a payment under this
Section 3(a)(i)(C), the Participant must be enrolled in the Company’s applicable health, dental, and vision benefits on the date of the Separation from Service. 

(ii) Subject to Section 13, the Company, at its expense, shall provide reasonable outplacement assistance to the
Participant, for a period not to exceed fifteen (15) months following the Participant’s Separation Date, from a professional outplacement assistance firm which is reasonably suitable to the Participant and commensurate with the
Participant’s position and responsibilities. In no event shall the amount expended for outplacement assistance for the Participant exceed One Thousand Dollars ($1,000) per month. 

(iii) The Participant shall be entitled to a pro-rata award of any award payable under the Company’s Short Term Incentive
Plan (“Incentive Plan”) based upon the Participant’s actual performance and the attainment of goals established under the Plan as determined by the Board in its sole discretion (consistent with applicable requirements under
Section 162(m) of the Code). Such pro-rata award shall be payable at the time such awards are payable under the Incentive Plan. The pro-rata portion shall be based on the number of days preceding the Separation Date in the performance period
during which the Separation Date occurs, divided by 365. 
 (b) A Participant who receives any payments and other benefits under this
Section 3 shall not be eligible for any severance-related payments or benefits under any employment-related agreement or plan, policy or program of the Company. The payments and other benefits under this Section 3 shall offset any amounts
due under the Worker Adjustment Retraining Notification Act of 1988 or any similar statute or regulation. 

  
 6 

 Section 4. Equity Awards. 

The following provisions apply to awards granted before March 5, 2013 under HRB’s 2003 Long-Term Executive Compensation, HRB’s
2013 Long Term Incentive Plan, or any predecessor plan. Awards granted under HRB’s 2013 Long Term Incentive Plan, or any successor plan, on or after March 5, 2013, vest and shall be exercisable as provided in the applicable award
agreement. 
 (a) Qualifying Termination 

(i) In the event a Participant incurs a Qualifying Termination: 

(A) with respect to any stock options outstanding on July 11, 2010, the Participant may exercise such options, to the
extent vested, until the earlier of: (a) fifteen (15) months following the Participant’s Separation Date and (b) the last day the options would have been exercisable if the Participant had not incurred a Separation from Service;

 (B) with respect to any stock options granted after July 11, 2010, any portion of stock option awards not vested as
of the Separation Date shall be forfeited; and 
 (C) with respect to any stock options granted after July 11,
2010, the Participant may exercise such options, to the extent vested, until the earlier of: (a) twelve (12) months following the Participant’s Separation Date and (b) the last day the options would have been exercisable if the
Participant had not incurred a Separation from Service. 
 (ii) In the event a Participant incurs a Qualifying Termination
any portion of restricted share or restricted share unit awards (other than performance shares) not vested as of the Separation Date shall be forfeited. 

(iii) In the event a Participant incurs a Qualifying Termination, such Participant shall be entitled to a pro-rata award of any
outstanding performance shares as of his or her Separation Date based on the achievement of the performance goals at the end of the then applicable performance period. Payment of such performance shares shall be made in a single lump sum as soon as
reasonably practicable upon the later of: (y) the expiration of the applicable performance period and (z) the date which is six (6) months following the Participant’s Separation from Service. 

(b) Change in Control Termination 

(i) In the event a Participant incurs a Change in Control Termination: 

(A) such Participant shall become 100% vested in all outstanding stock options; and 

(B) with respect to any options outstanding on July 11, 2010, the Participant may exercise such options, to the extent
vested, until the earlier of: (a) fifteen (15) months following the Participant’s Separation Date and (b) the last day the options would have been exercisable if the Participant had not incurred a Separation from Service; and

  
 7 

 (C) with respect to any stock options granted after July 11, 2010, the
Participant may exercise such options, to the extent vested, until the earlier of: (a) twelve (12) months following the Participant’s Separation Date and (b) the last day the options would have been exercisable if the Participant
had not incurred a Separation from Service. 
 (ii) In the event a Participant incurs a Change in Control Termination, such
Participant shall become 100% vested in all outstanding restricted shares or restricted share units awards (other than performance shares). 

(iii) In the event a Participant incurs a Change in Control Termination, such Participant shall be entitled to a pro-rata award
of any outstanding performance shares as of his or her Separation Date based on the achievement of the performance goals at the end of the then applicable performance period. Payment of such performance shares shall be made in a single lump sum as
soon as reasonably practicable upon the later of: (y) the expiration of the applicable performance period and (z) the date which is six (6) months following the Participant’s Separation from Service. 

Section 5. Repayment; Clawback. 

Notwithstanding any provision in this Plan to the contrary, if (i) the Company is required to restate any of its financial statements
filed with the Securities and Exchange Commission, other than restatements due solely to factors external to the Company such as a change in accounting principles or a change in securities laws or regulations with retroactive effect or (ii) the
Participant violates the provisions of any confidentiality, non-competition, non-solicitation or similar agreement or policy, then the Board may recover or require reimbursement of all severance, equity compensation awards (including profits from
the sale of Company stock acquired pursuant to such awards) and/or other payments or benefits made to the Participant under this Plan. In exercising its discretion to recover or require reimbursement of any amounts as a result of any restatement
pursuant to clause (i) above, the Board may consider, among other relevant factors, the level of the Participant’s responsibility or influence, as well as the level of others’ responsibility or influence, over the judgments or actions
that gave rise to the restatement. 
 Section 6. Other Payments. 

Upon any Separation from Service entitling the Participant to payments under this Plan, the Participant shall receive all accrued but unpaid
salary and all benefits accrued and payable under any plans, policies and programs of the Company, except for benefits payable under any severance plan, policy or arrangement of the Company. 

Section 7. Enforcement. 

If a Participant incurs any expenses associated with the successful enforcement of his or her rights under this Plan by arbitration, litigation
or other legal action, then the Company shall pay the Participant on demand of all reasonable expenses (including attorneys’ fees and legal expenses) incurred by the Participant in enforcing such rights under this Plan. The Participant shall
notify the Company of the expenses for which the Participant demands reimbursement within sixty (60) days after the Participant receives an invoice for such expenses, and the Company shall pay the reimbursement amount within fifteen
(15) days after receipt of such notice, subject to Section 13. For purposes of clarity, the Company shall have no obligation to reimburse the Participant for any expenses incurred by such Participant if any court, arbitrator, mediator or
other judicial panel rules in favor of the Company with respect to the dispute giving rise to such expenses. 

  
 8 

 Section 8. No Mitigation. 

A Participant shall not be required to mitigate the amount of any payment or benefit provided for in this Plan by seeking other employment or
otherwise, nor shall the amount of any payment or benefit provided for herein be reduced by any compensation earned by other employment or otherwise. 

Section 9. Nonexclusivity of Rights. 

Nothing in this Plan shall prevent or limit a Participant’s continued or future participation in or rights under any benefit, bonus,
incentive or other plan or program provided by the Company and for which the Participant may qualify, except as provided in this Plan. 

Section 10. No Set Off. 

The Company’s obligation to make the payments provided for in this Plan and otherwise to perform its obligations hereunder shall not be
affected by any circumstances, including, without limitation, any set-off, counterclaim, recoupment, defense or other right which the Company may have against the Participant or others. 

Section 11. Taxation. 

(a) To the extent applicable, this Plan shall be construed and administered consistently with Code Section 409A and the regulations and
guidance issued thereunder (“Section 409A”). For purposes of determining whether any payment made pursuant to this Plan results in a “deferral of compensation” within the meaning of Treasury Regulation 1.409A-1(b), the Company
shall maximize the exemptions described in such section, as applicable. Any reference to a “termination of employment” or similar term or phrase shall be interpreted as a “separation from service” within the meaning of
Section 409A. If any deferred compensation payment is payable while a Participant is a “specified employee” under Section 409A, and payment is due because of separation from service for any reason other than death, then payment
of such amount shall be delayed for a period of six months and paid in a lump sum on the first payroll payment date following the earlier of the expiration of such six month period or the Participant’s death. To the extent any payments under
this Plan are made in installments, each installment shall be deemed a separate payment for purposes of Section 409A and the regulations issued thereunder. A Participant or his or her beneficiary, as applicable, shall be solely responsible and
liable for the satisfaction of all taxes and penalties that may be imposed on such Participant or his or her beneficiary in connection with any payments to the Participant or his or her beneficiary pursuant to this Plan, including but not limited to
any taxes, interest and penalties under Section 409A, and the Company shall have no obligation to indemnify or otherwise hold a Participant or his or her beneficiary harmless from any and all of such taxes and penalties. 

(b) All payments and other benefits received by the Participant under this Plan shall be subject to all requirements of the law with regard to
tax withholding and reporting and filing requirements, and the Company shall use its best efforts to satisfy promptly all such requirements. 

Section 12. Section 280G Change in Control Payment. 

(a) In the event that it is determined that any payment or distribution in the nature of compensation (within the meaning of
Section 280G(b)(2) of the Code) to or for the benefit of a Participant, whether paid or payable or distributed or distributable pursuant to the terms of this Plan or otherwise (the “Change in Control Payment”), would constitute an
“excess parachute payment” within the meaning of Section 280G of the Code, then the Company shall pay to the Participant whichever of the 

  
 9 

 
following gives the Participant the highest net after-tax amount (after taking into account all applicable federal, state, local and security taxes): (1) the Change in Control Payment, or
(2) the amount that would not result in the imposition of excise tax on the Participant under Code Section 4999. Any required reduction in the Change in Control Payment pursuant to the foregoing shall be accomplished solely by reducing the
lump sum severance payment payable pursuant to Section 3(a)(i) of this Plan. 
 (b) All determinations to be made under this
Section 12 shall be made by an independent registered public accounting firm selected by the Company immediately prior to the Change in Control (the “Accounting Firm”), which shall provide its determinations and any supporting
calculations both to the Company and the Participant within ten (10) days of the Change in Control. Any such determination by the Accounting Firm shall be binding upon the Company and the Participant. All of the fees and expenses of the
Accounting Firm in performing the determinations referred to in this Section 12 shall be borne solely by the Company. 

Section 13. Reimbursements. 

Any reimbursements or in-kind benefits to be provided pursuant to this Plan (including, but not limited to under Section 3(a)(ii)) that
are taxable to the Participant shall be subject to the following restrictions: (a) each reimbursement must be paid no later than the last day of the calendar year following the calendar year during which the expense was incurred or tax was
remitted, as the case may be; (b) the amount of expenses or taxes eligible for reimbursement, or in kind benefits provided, during a calendar year may not affect the expenses or taxes eligible for reimbursement, or in-kind benefits to be
provided, in any other calendar year; and (c) the period during which any reimbursement may be paid or in-kind benefit may be provided shall end ten (10) years after termination of this Agreement; and (d) the right to reimbursement or
in-kind benefits is not subject to liquidation or exchange for another benefit. 
 Section 14. Term. 

This Plan is effective as of the Initial Effective Date and shall continue with respect to a Participant until the earliest of: (a) the
Participant’s Separation from Service, or (b) the date the Participant enters into a written separation agreement with the Company. 

Section 15. Successor Company. 

The Company shall require any successor or successors (whether direct or indirect, by purchase, merger or otherwise) to all or substantially
all of the business or assets of the Company to acknowledge expressly that this Plan is binding upon and enforceable against the Company in accordance with the terms hereof, and to become jointly and severally obligated with the Company to perform
this Plan in the same manner and to the same extent that the Company would be required to perform if no such succession or successions had taken place. 

Section 16. Notice. 

All notices and other communications required or permitted hereunder or necessary or convenient in connection herewith shall be in writing and
shall be delivered personally or mailed by registered or certified mail, return receipt requested, or by overnight express courier service, as follows: 

  
 10 

 If to the Company, to: 

H&R Block, Inc. 
 One H&R
Block Way 
 Kansas City, MO 64105 

Attention: Corporate Secretary 

If to the Participant, to the most recent address provided by the Participant to the Company for payroll purposes, or to such other address as
the Company or the Participant, as the case may be, shall designate by notice to the other party hereto in the manner specified in this Section 16; provided, however, that if no such notice is given by the Company following a Change in Control,
notice at the last address of the Company or any successor shall be deemed sufficient for the purposes hereof. Any such notice shall be deemed delivered and effective when received in the case of personal delivery, five (5) days after deposit,
postage prepaid, with the U.S. Postal Service in the case of registered or certified mail, or on the next business day in the case of overnight express courier service. 

Section 17. Amendment. 

This Plan may be amended at any time by the Board with respect to all or some of the Participants, provided that any such amendment may not
decrease or restrict a Participant’s rights under this Plan without his or her consent. 
 Section 18. Administration. 

The Plan shall be administered by the Board or by a committee of two or more members of the Board of Directors appointed by the Board which
shall have the exclusive discretion and authority to make, amend, interpret and enforce all appropriate rules and regulations for the administration of this Plan and to decide or resolve any and all questions that may arise in connection with the
Plan. To the extent the Board appoints a committee, any reference herein regarding the Board’s administration of the Plan shall be construed to apply to such committee. As of the date this amendment and restatement is effective, the Board
hereby appoints the compensation committee of the Board of Directors as administrators of the Plan (the “Compensation Committee”). 

Any decision or action of the Board with respect to any question arising out of or in connection with the administration, interpretation and
application of the Plan and the rules and regulations promulgated hereunder shall be final and conclusive and binding upon all persons having any interest in the Plan. In the administration of this Plan, the Board (or its appointed committee) may
employ agents and delegate to them such administrative duties as the Board deems appropriate (including acting through a duly appointed representative) and may from time to time consult with counsel who may be counsel to the Company. 

Except with respect to officers who are designated as executive officers by the Company’s Board of Directors under Section 16 of the
Securities Act of 1934, the Board (or its appointed committee) may delegate to one or more executive officers the authority, duties and responsibilities relating to the Company’s rights to prevent, enforce or remedy affirmative or restrictive
covenants contained either in this Plan or in a Participant’s Release Agreement, including the authority for such executive officer(s) to further delegate such authority, duties and responsibilities to any other individual or entity, whether or
not such person or entity is employed by, an officer of, or affiliated with the Company. 

  
 11 

 Section 19. No Right to Continued Employment. 

Nothing in this Plan shall be construed as giving the Participant any right to be retained in the employ of the Company. 

Section 20. Claims Procedure 

Any Participant may deliver to the Board a written claim for a determination with respect to the amounts distributable to such Participant from
the Plan. If such a claim relates to the contents of a notice received by the Participant, the claim must be made within sixty (60) days after such notice was received by the Participant. The claim must state with particularity the
determination desired by the Participant. All other claims must be made within 180 days of the date on which the event that caused the claim to arise occurred. 

The Board shall consider a Participant’s claim within seventy-five (75) days (unless special circumstances require additional time),
and shall notify the Participant in writing: (i) that the Participant’s requested determination has been made, and that the claim has been allowed in full; or (ii) that the Board has reached a conclusion contrary, in whole or in part,
to the Participant’s requested determination. Such notice must set forth in a manner calculated to be understood by the Participant and include the following information: 

(a) the specific reason(s) for the denial of the claim, or any part of it; 

(b) specific reference(s) to pertinent provisions of the Plan upon which such denial was based; 

(c) a description of any additional material or information necessary for the Participant to perfect the claim, and an
explanation of why such material or information is necessary; and 
 (d) an explanation of the claim review procedure set
forth below. 
 Within sixty (60) days after receiving a notice from the Board that a claim has been denied, in whole or in part, a
Participant (or the Participant’s duly authorized representative) may file with the Board a written request for a review of the denial of the claim. Thereafter, but not later than thirty (30) days after the review procedure began, the
Participant (or the Participant’s duly authorized representative): 
 (i) may review pertinent documents; 

(ii) may submit written comments or other documents; and/or 

(iii) may request a hearing, which the Board, in its sole discretion, may grant. 

The Board shall render its decision on review promptly, and not later than sixty (60) days after the filing of a written request for
review of the denial, unless a hearing is held or other special circumstances require additional time, in which case the Board’s decision must be rendered within 120 days after such date. Such decision must be written in a manner calculated to
be understood by the Participant, and it must contain: 

  
 12 

 (x) specific reasons for the decision; 

(y) specific reference(s) to the pertinent Plan provisions upon which the decision was based; and 

(z) such other matters as the Board deems relevant. 

A Participant’s compliance with the foregoing provisions of this Section 20 is a mandatory prerequisite to a Participant’s
right to commence any legal action with respect to any claim for benefits under this Plan. Service of legal process shall be made to: H&R Block Management, LLC, Attention: General Counsel, One H&R Block Way, Kansas City, Missouri 64105. 

Section 21. Governing Law. 

This Plan shall be governed by and interpreted under the laws of the State of Missouri without giving effect to any conflict of laws
provisions. Any legal action or proceeding with respect with this Plan shall be brought exclusively in the courts of the State of Missouri without regard to any conflicts of law. 

Section 22. Successors and Assigns. 

All of the terms and provisions of this Plan shall be binding upon and inure to the benefit of and be enforceable by the respective heirs,
representatives, successors and assigns of the parties hereto, except that the duties and responsibilities of the Participant and the Company hereunder shall not be assignable in whole or in part. 

Section 23. Severability. 

If any provision of this Plan or application thereof to anyone or under any circumstances shall be determined to be invalid or unenforceable,
such invalidity or unenforceability shall not affect any other provisions or applications of this Plan which can be given effect without the invalid or unenforceable provision or application. 

Section 24. Remedies Cumulative; No Waiver. 

No right conferred upon the Participant by this Plan is intended to be exclusive of any other right or remedy, and each and every such right or
remedy shall be cumulative and shall be in addition to any other right or remedy given hereunder or now or hereafter existing at law or in equity. No delay or omission by the Participant in exercising any right, remedy or power hereunder or existing
at law or in equity shall be construed as a waiver thereof. 
 Section 25. Headings. 

The captions of the articles, sections and paragraphs of this Plan are for convenience only and shall not control or affect the meaning or
construction of any of its provisions. 

  
 13 

 Section 26. Statement of ERISA Rights. 

In accordance with ERISA, each Participant shall be entitled to: 

(a) Examine, without charge (by contacting the Plan Administrator) all Plan documents and copies of all documents governing the
Plan and a copy of the latest annual report (Form 5500 series) filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration; 

(b) Obtain copies of all Plan documents and other Plan information upon written request to the Plan Administrator. A reasonable
fee may be charged for these copies; 
 (c) Receive a summary of the Plan’s annual financial report. The Plan
Administrator is required to furnish each Participant with a copy of this summary annual report; and 
 (d) Obtain a
statement showing the Participant’s account balance (if any). 
 In addition to creating rights for Plan Participants, ERISA imposes
duties upon the persons who are responsible for the operation of the Plan. The persons who operate the Plan are called “fiduciaries” and have a duty to operate the Plan prudently and in the interest of Plan Participants and beneficiaries.
No one, including the employer, may fire a Participant or otherwise discriminate against the Participant in any way to prevent the Participant from obtaining a benefit or exercising his or her rights under ERISA. If a claim for a benefit is denied
in whole or in part the Participant must receive a written explanation of the reason for the denial. The Participant has the right to have the Plan Administrator review and reconsider the claim. 

Under ERISA, there are steps a Participant can take to enforce the above rights. For instance, if a Participant may request any of the
materials listed above from the Plan Administrator and do not receive them within 30 days, the Participant may file suit in a federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay up to $110 a
day until the Participant receives the materials, unless the materials were not provided because of reasons beyond the control of the Plan Administrator. 

If a claim for benefits is denied or ignored, either in whole or in part, the Participant may file suit in a state or federal court. In the
event that Plan fiduciaries misuse the Plan’s funds, or if the Participant is discriminated against for asserting his or her rights, the Participant may seek assistance from the U.S. Department of Labor, or file suit in a federal court. The
court will decide who should pay court costs and legal fees. If a Participant is successful the court may order the person have sued to pay these costs and fees. But if the Participant loses, the court may order the Participant to pay these costs
and fees if, for example, it finds the claim is frivolous. 
 Any questions concerning the Plan should be directed to the Plan
Administrator. Additional information about this statement or a Participant’s rights under ERISA may be obtained from the nearest Office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in the telephone
directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W., Washington, D.C. 20210. A Participant may also obtain certain publications about his
or her rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration. 
 [The
remainder of this page is intentionally left blank] 

  
 14 

 IN WITNESS WHEREOF, the Company has executed this Plan this 8th day of November 2013. The H&R
Block Executive Severance Plan was initially adopted by HRB effective as of May 12, 2009. This amendment and restatement is effective November 8, 2013. 

 

			
	H&R BLOCK, INC.
		
	By:	 	/s/ Aileen Wilkins
		
	Title:	 	Chief People Officer

  
 15 

 EXHIBIT A 

SEVERANCE AND RELEASE AGREEMENT 

[EMPLOYEE] (“Employee”) and [EMPLOYING ENTITY], its parents, subsidiaries, affiliates, and assigns (collectively,
“Company”) enter into this Severance and Release Agreement (“Release Agreement”) under the terms and conditions recited below. 

I. Recitations 
 A.
Employee is currently employed as [TITLE]. Due to changing business needs, Employee has been notified and Employee has agreed that [his/her] employment will end on [TERM DATE] (the “Termination Date”). 

B. Employee and Company wish to enter into a full and final settlement of all issues and matters that exist between them, which include, but
are not limited to, any issues and matters that may have arisen out of Employee’s employment with or separation from Company. 
 C.
Employee specifically acknowledges that Company has advised [him/her] to seek [his/her] own personal legal counsel prior to signing this Release Agreement. 

D. In exchange for the mutual promises of Employee and Company set forth in this Release Agreement, Employee and Company agree to the terms and
conditions set forth below. 
 II. Basic Terms of the Release Agreement 

A. The parties agree to treat Employee’s separation from employment as a Qualifying Termination, but not a Change in Control Termination,
as defined in the H&R Block, Inc. Executive Severance Plan applicable to Employee (the “Plan”), a copy of which is attached to this Release Agreement as Exhibit A. Accordingly, following the Company’s receipt of a fully executed
copy of this Release Agreement, and provided that Employee does not revoke as permitted in paragraph III(A) below, Company agrees to provide Employee with the following payments and benefits to which [he/she] would be entitled under the Plan,
which shall be payable and provided in accordance with and subject to the terms of the Plan unless otherwise specified below: 
 1.
Severance Payment. Company will pay Employee a lump sum payment in the amount of $[insert amount], less applicable tax withholdings. 

2. COBRA Subsidy. Company will pay Employee a lump sum payment of $[insert amount], less applicable tax withholdings, which represents
an amount equal to the Company’s regular monthly premium toward the Employee’s health and welfare benefits as of Employee’s last day worked multiplied by twelve (12) months. 

3. Short-Term Incentive Payment. Company will pay Employee a pro-rata award of any award payable under any applicable Short-Term
Incentive (“STI”) Plan for fiscal year [insert applicable year] based upon Employee’s actual performance and the Company’s attainment of goals established under the STI Plan as determined by the H&R Block, Inc. Board
of Directors in its sole discretion. Such pro-rata award, if any, shall be payable in accordance with the Company’s short-term incentive process and subject to the terms and conditions of any applicable STI Plan. Company will pay Employee any
short term incentive award due [him/her] at the time such awards are generally payable under the applicable STI Plan to other participants. 

 4. Stock Options. With respect to those portions of any incentive stock options
(“ISO”) and nonqualified stock options (“NQSO”) to purchase shares of H&R Block, Inc.’s common stock granted to Employee under the 2003 Long-Term Executive Compensation Plan (or any predecessor or successor plan) and
outstanding on July 11, 2010 and that are vested, Employee may exercise such options until the earlier of (a) fifteen (15) months following the Termination Date; or (b) the last day the options would have been exercisable if
Employee had not incurred a separation from service. Those portions of any ISO and NQSO to purchase shares of H&R Block, Inc.’s common stock granted to Employee after July 11, 2010 that are not vested as of the Termination Date shall
be forfeited. With respect to those portions of any ISO and NQSO that were granted after July 11, 2010 and before March 5, 2013 and that are vested as of the Termination Date, Employee shall have until the earlier of (a) twelve
(12) months following the Termination Date; or (b) the last day the options would have been exercisable if Employee had not incurred a separation from service to exercise such options. Any ISO and NQSO that were granted on or after
March 5, 2013 shall vest and be exercisable as provided in the applicable award agreement. A list of the stock options vested as of the Termination Date and that shall be forfeited on the Termination Date is attached as Exhibit B. 

5. Performance Shares. Employee will vest in a pro-rata portion of any outstanding performance shares granted to Employee before
March 5, 2013 under the 2003 Long-Term Executive Compensation Plan (or any predecessor or successor plan) and held by Employee on the Termination Date. Employee shall become entitled to payment of such vested portion of such performance shares
pursuant to the provisions of the applicable award agreement based on the achievement of the performance goals at the end of the then-applicable performance period. Any performance shares that were granted to Employee on or after March 5, 2013
shall vest as provided in the applicable award agreement. A list of the performance shares outstanding as of the Termination Date and that shall be forfeited on the Termination Date is attached as Exhibit C. 

6. Restricted Shares and Restricted Share Units. All restricted shares or restricted share units granted to Employee after
July 11, 2010 and before March 5, 2013 that are not vested as of the Termination Date shall be forfeited. Any restricted shares or restricted share units granted to Employee on and after March 5, 2013 shall vest as provided in the
applicable award agreement. A list of the Restricted Shares and Restricted Share Units outstanding as of the Termination Date and that shall be forfeited on the Termination Date is attached as Exhibit D. 

7. Outplacement Services. Company will pay an amount not to exceed $1,000.00 per month directly to a professional outplacement
assistance firm which is reasonably suitable to Employee until the earlier to occur of (a) the date Employee obtains other employment; or (b) fifteen (15) months following the Termination Date. 

B. Employee agrees to the following: 

1. Release of Claims. Employee agrees to and hereby does release and forever discharge Company, and each and every one of its component,
predecessor and successor companies, and their respective past and present agents, officers, executives, employees, attorneys, and directors (collectively the “Released Parties”) from any and all matters, claims, charges, demands, damages,
causes of action, debts, liabilities, controversies, claims for attorneys’ fees, judgments, and suits of every kind and nature whatsoever, foreseen or unforeseen, known or unknown, which have arisen between Employee and the Released Parties up
to the date Employee signs this Release Agreement, all as more fully set forth in paragraphs IV(A) through (E) below. 

  
 Exhibit A –
Page 2 

 2. Confidential Information. Employee agrees that [he/she] will not, without the
prior written consent of Company, directly or indirectly use for the benefit of any person or entity other than Company, or make known, divulge or communicate to any person, firm, corporation or other entity, any confidential or proprietary
information, knowledge or trade secrets acquired, developed or learned of by Employee during [his/her] employment with Company. Employee shall not retain after the Termination Date, any document, record, paper, disk, tape or compilation of
information relating to any such confidential information. 
 3. Return of Company Property. Employee shall return to Company by the
Termination Date, any and all things in [his/her] possession or control relating to Company, including but not limited to any equipment issued to Employee, all correspondence, reports, contracts, financial or budget information, personnel or
labor relations files, office keys, manuals, and all similar materials not specifically listed here. Employee further agrees that as of the Termination Date [he/she] will have no outstanding balance on [his/her] corporate credit card
for which appropriate travel and expense accounting has not been submitted. 
 4. Legal Hold. To the extent Employee has
received a Preservation Notice/Legal Hold from the Legal Department, Employee shall take all necessary steps to preserve information related in any way to the Preservation Notice/Legal Hold in its original format and location and will not modify,
delete or destroy such information. Employee will notify the Legal Department of the nature and location of any and all such information. 

5. Confidentiality & Restrictive Covenant Agreement. Employee acknowledges that [he/she] entered into a
Confidentiality & Restrictive Covenant Agreement with the Company (the “Confidentiality Agreement”), which is attached as Exhibit E. Employee agrees that [he/she] is bound by the provisions of the Confidentiality
Agreement and will continue, after the Termination Date, to abide by the terms of the Confidentiality Agreement. 
 6.
Non-disparagement. Employee agrees [he/she] will not disparage Company or make or solicit any comments to the media or others that may be considered derogatory or detrimental to the good business name or reputation of Company. This
clause has no application to any communications with the Equal Employment Opportunity Commission or any state or local agency responsible for investigation and enforcement of discrimination laws. 

7. Employee Availability/Cooperation. Employee agrees to make [himself/herself] reasonably available to the Company to respond
to requests for information pertaining to or relating to the Company, or any predecessor and successor companies, or their respective past and present agents, officers, executives, employees, attorneys, directors, and assigns. Employee also agrees
to reasonably assist and cooperate with the Company (and their outside counsel) in connection with the defense or prosecution of any claim that may be made or threatened against or by the Company, or in connection with any ongoing or future
investigation or dispute or claim of any kind involving the Company, including any proceeding before any arbitral, administrative, judicial, legislative, or other body or agency, including preparing for and testifying in any proceeding to the extent
such claims, investigations or proceedings relate to services performed or required to be performed by Employee, pertinent knowledge possessed by Employee, or any act or omission by Employee. Employee will perform all acts and execute and deliver
any documents that may be reasonably necessary to carry out the provisions of this paragraph. Upon presentment to the Company of appropriate documentation, the Company will pay directly or reimburse Employee for the reasonable out-of pocket expenses
incurred as a result of such cooperation.  

  
 Exhibit A –
Page 3 

 8. Resignation. Employee agrees that, upon the Termination Date, [he/she] resigns
from all offices, directorships, trusteeships, committee memberships, and fiduciary capacities held with, or on behalf of, the Company, and any benefit plans of the Company. Employee will execute the resignations attached as Exhibit F
contemporaneously with [his/her] execution of this Release Agreement, and agrees to reasonably cooperate with the Company to execute any additional resignations that the Company may determine to be required upon its further review of
applicable requirements to which it is subject. 
 III. Acknowledgments and Additional Terms 

A. Consideration/Revocation Period. Employee shall have twenty-one (21) days following [his/her] receipt of this Release
Agreement to consider whether or not to sign this Release Agreement. Employee acknowledges that [he/she] may revoke [his/her] acceptance of the terms and conditions of this Release Agreement at any time within seven (7) calendar
days after the day on which [he/she] originally returned [his/her] signed copy of the Release Agreement to the Company. Such revocation, to be effective, must be delivered by written notice, in a manner so the notice is received on or
before the seventh day by: General Counsel, H&R Block, Inc., One H&R Block Way, Kansas City, MO 64105. In the event Employee does not return an executed copy of this Release Agreement to the Company within the twenty-one (21) day
period, or Employee revokes [his/her] acceptance of the terms and conditions of this Release Agreement within the seven (7) day period following [his/her] execution of this Release Agreement, Employee will not be entitled to any
of the payments or benefits provided under paragraph II(A). 
 B. Opportunity to Consult Personal Attorney. Employee acknowledges that
Company has advised [him/her] to seek [his/her] own legal counsel prior to signing this Release Agreement and that [he/she] has consulted or has had the opportunity to consult with [his/her] personal attorney prior to
executing this Release Agreement. 
 C. No Admission of Liability. Employee and Company agree that nothing in this Release Agreement
is an admission by either of any wrongdoing, and that nothing in this Release Agreement is to be construed as such by anyone. 
 D.
Consideration. Employee agrees that provision of the payments and benefits set forth in paragraph II(A) and the Plan constitute payments and benefits to which Employee is not otherwise entitled and constitutes valuable consideration for the
promises and representations made by Employee in this Release Agreement . 
 E. Choice of Law. All disputes which arise out of the
interpretation and enforcement of this Release Agreement shall be governed by the laws of the State of Missouri without giving effect to its choice of law provisions. 

F. Entire Agreement. This Release Agreement, including Exhibits B through F attached hereto, constitute the entire agreement between the
parties related to the subject matters set forth in this Release Agreement. The parties acknowledge the terms of the Plan can be terminated or changed according to the terms set forth in the Plan. The parties acknowledge the terms of this Release
Agreement can only be changed by a written amendment to the Release Agreement signed by both parties. 

  
 Exhibit A –
Page 4 

 G. No Reliance. The parties have not relied on any representations, promises, or
agreements of any kind made to them in connection with this Release Agreement, except for those set forth in writing in this Release Agreement or in the Plan. 

H. Separate Signatures. Separate copies of this Release Agreement shall constitute originals which may be signed separately but which
together will constitute one single agreement. 
 I. Effective Date. This Release Agreement becomes effective and binding on the
eighth calendar day following Employee’s execution of the Release Agreement pursuant to paragraph III(A). 
 J.
Severability. If any provision of this Release Agreement, including the Plan, is held to be invalid, the remaining provisions shall remain in full force and effect. In addition, if a court of competent jurisdiction determines
the restrictions contained in the Confidentiality Agreement attached as Exhibit E to be invalid, illegal, or otherwise unenforceable or unreasonable in scope, the validity, legality, and enforceability of the other provisions of this Release
Agreement shall not be affected thereby. Any such restriction(s) in the Confidentiality Agreement determined by a court of competent jurisdiction to be invalid, illegal, or otherwise unenforceable or unreasonable will be considered by the Company
and Employee to be amended as to the scope of protection, time and geographic area in whatever manner, if any, is considered reasonable by that court and, as so amended, will be enforced.  

K. Continuing Obligations. Any continuing obligations Employee has after separation of employment pursuant to any written agreement with
Company, the Plan, or by operation of law are intended to survive this Release Agreement. The terms of this Release Agreement add to any such obligations and are not intended to otherwise modify them in any way. 

L. Compensation, Injuries, Leave, Ethics. Employee acknowledges that: (1) upon receipt of a final paycheck, Employee has received
all compensation due through the Termination Date as a result of services performed for Company, except as otherwise provided in this Agreement; (2) Employee has reported to Company any and all work-related injuries incurred during employment;
(3) Company properly provided any requested leave of absence because of Employee’s or a family member’s health condition and Employee has not been subjected to any improper treatment, conduct or actions due to a request for or taking
such leave; and (4) Employee has provided the Company with written notice of any and all concerns regarding suspected ethical and compliance issues or violations on the part of Company. 

M. 409A Representations. Company has made a good faith effort to comply with current guidance under Section 409A of the Internal
Revenue Code. Notwithstanding the foregoing or any provision in this Agreement to the contrary, Company does not warrant or promise compliance with Section 409A, and Employee understands and agrees that [he/she] shall not have any claim
against Company with respect to Section 409A or for any good faith effort taken to comply with Section 409A. 
 IV. Release

 A. In consideration of the recitations and agreements listed above, Employee releases, and forever discharges Company and each and every
one of its component, predecessor, and successor companies, and their respective past and present agents, officers, executives, employees, attorneys, and directors (collectively the “Released Parties”), from any and all matters, claims,
charges, demands, damages, causes of action, debts, liabilities, controversies, claims for attorneys’ fees, judgments, and suits of every kind and nature whatsoever, foreseen or unforeseen, known or unknown, which have arisen between Employee
and the Released Parties up to the date Employee signs this Release Agreement. 

  
 Exhibit A –
Page 5 

 B. This release of claims includes, but is not limited to: (1) any claims Employee may have
relating to any aspect of [his/her] employment with the Released Parties and/or the separation of that employment; (2) any breach of an actual or implied contract of employment between Employee and the Released Parties; (3) any
claim of unjust or tortious discharge; (4) any common law claim (including but not limited to fraud, negligence, intentional or negligent infliction of emotional distress, negligent hiring/retention/supervision, or defamation); (5) any
claims arising under (i) the Civil Rights Act of 1866, 42 U.S.C. § 1981, (ii) the Civil Rights Act of 1964, 42 U.S.C. §§ 2000e, et seq., as amended by the Civil Rights Act of 1991, (iii) the Age Discrimination in
Employment Act, 29 U.S.C. §§ 621, et seq. (including but not limited to the Older Worker Benefit Protection Act), (iv) the Employee Retirement Income Security Act, 29 U.S.C. §§ 1001, et seq., (v) the Rehabilitation Act
of 1973, 29 U.S.C. §§ 701, et seq., (vi) the American with Disabilities Act, 42 U.S.C. §§ 12101, et seq., (vii) the Occupational Safety and Health Act, 29 U.S.C. §§ 651, et. seq., and (viii) the Worker
Adjustment and Retraining Notification Act, 29 U.S.C. §§ 2101, et seq.; (6) any applicable state or local employment discrimination statute or ordinance; and (7) any other federal, state, or local statutes or ordinances. 

C. Employee represents and warrants that, as of the date [he/she] signs this Release Agreement, [he/she] has not filed or
commenced any suit, claim, charge, complaint, or other legal proceeding of any kind against the Released Parties. 
 D. The above release
does not waive claims: (1) for unemployment or workers’ compensation; (2) for vested rights under ERISA-covered employee benefit plans as applicable on the date Employee signs this Release Agreement; (3) that may arise after
Employee signs this Release Agreement; or (4) which cannot be released by private agreement. Nothing in this release generally prevents Employee from filing a charge or complaint with, or from participating in an investigation or proceeding
conducted by, the Equal Employment Opportunity Commission or any other federal, state or local agency charged with the enforcement of any employment laws, although by signing this Release Agreement, Employee waives the right to individual relief
based on claims asserted in such a charge or complaint, except before the National Labor Relations Board or anywhere else such a waiver is prohibited. 

E. Employee agrees [he/she] waives any right to participate in any settlement, verdict or judgment in any class, collective or
multi-party action against the Released Parties arising from conduct occurring on or before the date Employee signs this Release Agreement, and that [he/she] waives any right to accept anything of value or any injunctive relief associated
with any such pending or threatened class action against the Released Parties. 
 THIS IS A RELEASE OF CLAIMS – READ CAREFULLY
BEFORE SIGNING 
 I have read this Severance and Release Agreement. Company advised me to seek the advice of counsel regarding the
meaning and effect of this Release Agreement, and I have had the opportunity to do so. I fully understand the terms of this Release Agreement and I understand it is a complete and final release of any of my claims against the Released Parties (as
defined in this Release Agreement). I sign the Release Agreement as my own free act and deed. 

  
 Exhibit A –
Page 6 

 
			
	[EMPLOYEE NAME]
	
	 
		
	Date:	 	 
	
	[EMPLOYING ENTITY]
		
	 	 	 
		
	By:	 	
		
	Title:	 	
		
	Date:	 	 

  
 Exhibit A –
Page 7 

 EXHIBIT A 

H&R BLOCK, INC. EXECUTIVE SEVERANCE PLAN 

  
 Exhibit A –
Page 8 

 EXHIBIT B 

STOCK OPTION SUMMARY 

  
 Exhibit A –
Page 9 

 EXHIBIT C 

PERFORMANCE SHARES SUMMARY 

  
 Exhibit A –
Page 10 

 EXHIBIT D 

RESTRICTED SHARES & RESTRICTED SHARE UNITS SUMMARY 

  
 Exhibit A –
Page 11 

 EXHIBIT E 

CONFIDENTIALITY & RESTRICTIVE COVENANT AGREEMENT 

  
 Exhibit A –
Page 12 

 EXHIBIT F 

RESIGNATION 
 To Whom It May
Concern: 
 Effective [INSERT DATE], I hereby resign from the following officer and director positions: 

 

			
	  
 Entity
Name
	 	  

    Title

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

  
  
  

			
	  

	[EMPLOYEE NAME]
		
	Dated:	 	 

  
 Exhibit A –
Page 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]